



#23

Page 1

IN THE UNITED STATES
PATENT AND TRADEMARK OFFICE

APPLICANT:

Yamanouchi)
Pharmaceutical)
Co., Ltd.)
) DATE: December 20, 2004

U.S. PATENT NO.:

6,017,927)
)
)

ISSUED:

January 25, 2000)

Application for Extension of
Patent Term Pursuant to 35 U.S.C. § 156

Mail Stop: Patent Extension
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RECEIVED
DEC 23 2004
OFFICE OF PETITIONS

Yamanouchi Pharmaceutical Co., Ltd (“Yamanouchi” or “the Applicant”), Assignee of the above-identified patent, hereby petitions for extension of U.S. Patent No. 6,017,927 pursuant to 35 U.S.C. § 156(d) and 37 C.F.R. § 1.740, and states in part thereof as follows:

(1) A COMPLETE IDENTIFICATION OF THE APPROVED PRODUCT AS
BY APPROPRIATE CHEMICAL AND GENERIC NAME, PHYSICAL
STRUCTURE OR CHARACTERISTICS.

The United States Food and Drug Administration (“FDA”) has approved a New Drug Application (“NDA”) (NDA # 21-518) for a human drug product, *i.e.*, VESIcare® (solifenacin succinate) film-coated tablet (hereinafter “Product”), which is effective for relief of symptoms of urinary frequency, urinary urgency or urinary incontinence associated with overactive bladder. The chemical name of solifenacin is:

(+)-(1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate


(1S)-(3R)-1-azabicyclo[2.2.2]oct-3-yl 3,4-dihydro-1-phenyl-2(1H)-isoquinolinecarboxylate; or

(3R)-3-quinuclidinyl (1S)-1-phenyl-1,2,3,4-tetrahydro-2- isoquinolinecarboxylate; or

12/21/2004 55555HE1 00000028 194880 6017927
01 FC:1983 1020.00 DA
1457)

(3*R*)-1-azabicyclo[2.2.2]oct-3yl (1*S*)-1-phenyl-3,4-dihydroisoquinoline-2(1*H*)-carboxylate.

with a molecular formula of C₂₃H₂₆N₂O₂·C₄H₆O₄, a molecular weight of 480.56, and a structural formula of:



(2) **A COMPLETE IDENTIFICATION OF THE FEDERAL STATUTE INCLUDING THE APPLICABLE PROVISION OF LAW UNDER WHICH THE REGULATORY REVIEW OCCURRED.**

The regulatory review occurred under § 505 of the Federal Food, Drug, and Cosmetic Act (“FDC Act”), 21 U.S.C. § 355.

(3) **AN IDENTIFICATION OF THE DATE ON WHICH THE PRODUCT RECEIVED PERMISSION FOR COMMERCIAL MARKETING OR USE UNDER THE PROVISION OF LAW UNDER WHICH THE APPLICABLE REGULATORY REVIEW PERIOD OCCURRED.**

FDA approved NDA #21-518 for VESIcare® (solifenacain succinate) film-coated tablet for commercial marketing under § 505(b) of the FDC Act on November 19, 2004.

(4) **IN THE CASE OF A DRUG PRODUCT, AN IDENTIFICATION OF EACH ACTIVE INGREDIENT IN THE PRODUCT AND AS TO EACH ACTIVE INGREDIENT, A STATEMENT THAT IT HAS NOT BEEN PREVIOUSLY APPROVED FOR COMMERCIAL MARKETING OR USE UNDER THE FDC ACT, THE PUBLIC HEALTH SERVICE ACT, OR THE VIRUS-SERUM-TOXIN ACT, OR A STATEMENT OF WHEN THE ACTIVE INGREDIENT WAS APPROVED FOR COMMERCIAL MARKETING OR USE (EITHER ALONE OR IN COMBINATION WITH OTHER ACTIVE**

INGREDIENTS), THE USE FOR WHICH IT WAS APPROVED, AND THE PROVISION OF LAW UNDER WHICH IT WAS APPROVED.

The only active ingredient in the Product (which is a human drug) is solifenacin succinate. FDA has not previously approved solifenacin succinate for commercial marketing or use under the FDC Act, the Public Health Service Act, or the Virus-Serum-Toxin Act.

(5) **A STATEMENT THAT THE APPLICATION IS BEING SUBMITTED WITHIN THE SIXTY DAY PERIOD PERMITTED FOR SUBMISSION PURSUANT TO 37 C.F.R. § 1.720(f) AND AN IDENTIFICATION OF THE DATE OF THE LAST DAY ON WHICH THE APPLICATION COULD BE SUBMITTED.**

FDA approved the Product on November 19, 2004. The last day within the sixty-day period permitted for submission of an application for extension of a patent is January 18, 2005. This application is being submitted before January 18, 2005.

(6) **A COMPLETE IDENTIFICATION OF THE PATENT FOR WHICH AN EXTENSION IS BEING SOUGHT BY THE NAME OF THE INVENTOR, THE PATENT NUMBER, THE DATE OF ISSUE, AND THE DATE OF EXPIRATION.**

The patent for which an extension is being sought is U.S. Patent No. 6,017,927, which issued on January 25, 2000 to Makoto Takeuchi, Ryo Naito, Masahiko Hayakawa, Yoshinori Okamoto, Yasuhiro Yonetoku, Ken Ikeda, and Yasuo Isomura, and which is assigned to Yamanouchi Pharmaceutical Co., Ltd. The assignment was recorded in the USPTO on August 28, 1997, at reel 008827, frame 0376. A copy of the assignment of the patent to Yamanouchi is attached hereto as Attachment 1. U.S. Patent No. 6,017,927 is scheduled to expire on December 27, 2015.

(7) **A COPY OF THE PATENT FOR WHICH AN EXTENSION IS BEING SOUGHT, INCLUDING THE ENTIRE SPECIFICATION (INCLUDING CLAIMS) AND DRAWINGS.**

A copy of U.S. Patent No. 6,017,927 is attached hereto as Attachment 2.

(8) **A COPY OF ANY DISCLAIMER, CERTIFICATE OF CORRECTION, RECEIPT OF MAINTENANCE FEE PAYMENT, OR REEXAMINATION CERTIFICATE ISSUED IN THE PATENT.**


There are no disclaimers or reexamination certificates. Certificates of correction and a maintenance fee payment receipt are attached hereto as Attachments 3A, 3B, and 3C.

(9) **A STATEMENT THAT THE PATENT CLAIMS THE APPROVED PRODUCT, OR A METHOD OF USING OR MANUFACTURING THE APPROVED PRODUCT, AND A SHOWING WHICH LISTS EACH APPLICABLE PATENT CLAIM AND DEMONSTRATES THE MANNER IN WHICH AT LEAST ONE SUCH PATENT CLAIM READS ON THE APPROVED PRODUCT.**

U.S. Patent No. 6,017,927 claims the Product and also claims a composition of matter comprising the drug product.

Claim 1

A quinuclidine derivative represented by the following formula (I):



where the symbols in the formula have the following meanings: Ring A:

- (1) an aryl group having 6 to 14 carbon atoms
- (3) a cycloalkyl group having 3 to 8 carbon atoms
- (4) a cycloalkenyl group having 3 to 8 carbon atoms;

wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group,

a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group, and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or mono- or di-lower alkylamino group

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2,

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof.

Claim 2

The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 1, wherein R represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group, and the ring A represents an aryl group having 6 to 14 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms or a cycloalkenyl group having 3 to 8 carbon atoms, in which said ring may be substituted by a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group.

Claim 3

The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 2, wherein m is 0, and the ring A represents an aryl group, a cycloalkyl group or a cycloalkenyl group which may be substituted by a halogen atom, a

lower alkyl group, a hydroxyl group or a lower alkoxy group.

Claim 4

The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 3, wherein the ring A represents a phenyl group which may be substituted by a halogen atom or a lower alkyl group, or cycloalkyl group.

Claim 5


The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to any one of claims 2 to 4, wherein X represents a single bond.

Claim 6

A quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to any one of claim 1, which is selected from the group consisting of 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate, and 3-quinuclidinyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate.

Claim 7

A pharmaceutical composition which comprises a quinuclidine derivative represented by the following formula (I):



where the symbols in the formula have the following meanings: Ring A:

- (1) an aryl group having 6 to 14 carbon atoms
- (3) a cycloalkyl group having 3 to 8 carbon atoms
- (4) a cycloalkenyl group having 3 to 8 carbon atoms;

wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or mono- or di-lower alkylamino group

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group, an alkoxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2, or
a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof,
and a pharmaceutically acceptable carrier.

The applicable patent claims which read on the Product are Claims 1,2,3,4,5,6 and 7.

Claim 1 reads on the Product because the Product is the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of the formula of Claim 1 wherein Ring A is a phenyl group, which is (1) an aryl group having 6 to 14 carbon atoms, X is a single bond, l is 0, m is 0, n is 2 and R does not exist, because m is 0.

Claim 2 reads on the Product because the Product is the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of Claim 1 wherein Ring A is a phenyl group, which is an aryl group having 6 to 14 carbon atoms and R does not exist, because m is 0.

Claim 3 reads on the Product because the Product is the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of Claim 2 wherein m is 0, Ring A is a phenyl group, which is an aryl group.

Claim 4 reads on the Product because the Product is the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of Claim 3 wherein Ring A is a phenyl group.

Claim 5 reads on the Product because the Product is the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of any one of Claims 2 to 4 wherein X is a single bond.

Claim 6 reads on the Product because the Product is the succinate of the (+) optically active isomer of the compound specifically named in Claim 6.

Claim 7 reads on the Product because the Product is a pharmaceutical composition which comprises the succinate of the (+) optically active isomer of (1S,3'R)-quinuclidin-3'-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate which is a compound of the formula of Claim 7 wherein Ring A is a phenyl group, which is (1) an aryl group having 6 to 14 carbon atoms, X is a single bond, l is 0, m is 0, n is 2 and R does not exist, because m is 0.

(10) A STATEMENT BEGINNING ON A NEW PAGE OF THE RELEVANT DATES AND INFORMATION PURSUANT TO 35 U.S.C. 156(g) IN ORDER TO ENABLE THE SECRETARY OF HEALTH AND HUMAN SERVICES OR THE SECRETARY OF AGRICULTURE, AS APPROPRIATE, TO DETERMINE THE APPLICABLE REGULATORY REVIEW PERIOD.

The relevant dates and information pursuant to 35 U.S.C. § 156(g) needed to enable the Secretary of Health and Human Services to determine the applicable regulatory review period are as follows:

The Investigational New Drug Application (“IND”) for the Product became effective on May 5, 1999 (IND #58,135).

New Drug Application (“NDA”) #21-518 was submitted to FDA on December 19, 2002.

FDA approved NDA #21-518 on November 19, 2004.

**(11) A BRIEF DESCRIPTION BEGINNING ON A NEW PAGE OF THE
SIGNIFICANT ACTIVITIES UNDERTAKEN BY THE MARKETING
APPLICANT DURING THE APPLICABLE REGULATORY REVIEW PERIOD
WITH RESPECT TO THE APPROVED PRODUCT AND THE SIGNIFICANT
DATES APPLICABLE TO SUCH ACTIVITIES.**

| DATE TO FDA | DESCRIPTION |
|-------------------|--|
| 02 Apr. 1999 | Initial IND Application |
| 17 Jun. 1999 | Protocol Amendment Information Amendment: Pharm/Tox |
| 09 Dec. 1999 | Information Amendment: Clinical |
| 03 March 2000 | Protocol Amendment |
| 12 Apr. 1999 | Information Amendment: Pharm/Tox; Clinical Protocol Amendment |
| 30 June 2000 | Annual Report |
| 01 Sept. 2000 | Protocol Amendment |
| 14 Sept. 2000 | Information Amendments: Chemistry, Pharm/Tox, Clinical |
| 18 Oct. 2000 | Protocol Amendment: Updated Investigators Brochure |
| 16 Nov. 2000 | Protocol Amendment |
| 05 Dec. 2000 | Information Amendment |
| 21 Dec. 2000 | Information Amendment: Toxicology, Chemistry |
| 01 Feb. 2001 | Protocol Amendment |
| 16 Feb. 2001 | Request for Comment |
| 21 February 2001 | Information Amendment |
| 27 February 2001 | Protocol Amendment |
| 21 March 2001 | Protocol Amendment |
| 09 April 2001 | Protocol Amendment |
| 03 May 2001 | Protocol Amendment |
| 30 May 2001 | Protocol Amendment |
| 01 June 2001 | Information Amendment |
| 18 June 2001 | Protocol Amendment |
| 29 June 2001 | Annual Report |
| 05 July 2001 | Information Amendments |
| 13 July 2001 | Information Amendment |
| 17 July 2001 | Protocol Amendment |
| 14 August 2001 | Protocol Amendment |
| 17 August 2001 | Protocol Amendment |
| 19 September 2001 | Protocol Amendment |
| 28 September 2001 | Protocol Amendment |
| 19 October 2001 | Protocol Amendments |
| 01 November 2001 | Protocol Amendments |

| DATE TO FDA | DESCRIPTION |
|-------------------|--|
| 09 November 2001 | Other Amendment: Statistical Analysis Plan |
| 06 December 2001 | Protocol Amendment |
| 21 January 2002 | Protocol Amendment |
| 25 January 2002 | Other Amendment |
| 29 January 2002 | Other Amendment |
| 13 February 2002 | Protocol Amendment |
| 14 February 2002 | Other Amendment |
| 15 February 2002 | Other Amendment |
| 18 February 2002 | Other Amendment |
| 26 February 2002 | Other Amendment |
| 06 March 2002 | Other Amendment |
| 14 March 2002 | Information Amendment: Pharmacology/Toxicology, Clinical |
| 22 March 2002 | Other Amendment: Investigator's Brochure |
| 11 June 2002 | Protocol Amendment |
| 01 July 2002 | Annual Report |
| 06 August 2002 | Protocol Amendment |
| 27 August 2002 | Other Amendment |
| 25 September 2002 | Other Amendment |
| 30 September 2002 | Other Amendment |
| 19 December 2002 | New Drug Application #21-518 |
| 24 January 2003 | Protocol Amendment |
| 19 February 2003 | Protocol Amendments |
| 27 February 2003 | Information Amendment |
| 26 March 2003 | NDA Field Copy Submission |
| 03 April 2003 | Information Amendment |
| 11 April 2003 | Information Amendment |
| 25 April 2003 | 4-Month safety update |
| 06 May 2003 | Protocol Amendment |
| 08 May 2003 | CMC Amendment |
| 13 May 2003 | Information Amendment |
| 13 June 2003 | CMC Amendment |
| 16 June 2003 | Clinical Amendment |
| 26 June 2003 | Information Amendment |
| 15 July 2003 | Information Amendment |
| 28 July 2003 | Information Amendment |
| 25 August 2003 | Information Amendment |
| 29 August 2003 | Information Amendment |
| 11 September 2003 | Information Amendment |
| 19 September 2003 | Draft Labeling |
| 22 September 2003 | Information Amendment |

| DATE TO FDA | DESCRIPTION |
|-------------------|--|
| 26 September 2003 | Response to FDA Request for Information |
| 03 October 2003 | Response to FDA Request for Information |
| 09 October 2003 | Response to FDA Request for Information |
| 15 October 2003 | Response to FDA Request for Information |
| 16 October 2003 | Response to FDA Request for Information |
| 20 October 2003 | Response to FDA Approvable Letter |
| 11 November 2003 | Protocol Amendment |
| 09 December 2003 | Information Amendment |
| 24 March 2004 | Response to FDA Request for Information |
| 18 May 2004 | Complete Response to Approvable Letter of October 17, 2003 |
| 18 June 2004 | Clinical Amendment |
| 17 September 2004 | Information Amendment |
| 24 September 2004 | Information Amendment |
| 30 September 2004 | Information Amendment |
| 29 October 2004 | Response to FDA Comments |
| 01 November 2004 | Response to FDA Comments |
| 08 November 2004 | Response to FDA Comments |
| 17 November 2004 | Response to FDA Comments |
| 18 November 2004 | Submission of Final Draft Labeling |

(12) A STATEMENT BEGINNING ON A NEW PAGE THAT IN THE OPINION OF THE APPLICANT THE PATENT IS ELIGIBLE FOR THE EXTENSION AND A STATEMENT AS TO THE LENGTH OF EXTENSION CLAIMED, INCLUDING HOW THE LENGTH OF EXTENSION WAS DETERMINED.

It is the opinion of Yamanouchi that U.S. Patent No. 6,017,927 is eligible for extension, because: (a) the patent claims the Product or a method of using the Product; (b) the term of the patent has never been extended; (c) this application is submitted in compliance with all requirements of 37 C.F.R. § 1.740; (d) the Product has been subject to a regulatory review period as defined in 35 U.S.C. § 156(g) before its commercial marketing or use; (e) Yamanouchi has received permission from FDA for commercial marketing or use of the Product and the permission for the commercial marketing or use of the Product is the first received permission for commercial marketing or use under the provision of law under which the applicable regulatory review occurred; (f) this Application for Extension is submitted within the sixty-day period after the Product first received permission for commercial marketing and use; (g) the term of the patent has not expired before submission of this Application for Extension; and (h) no other patent term has been extended for the same regulatory review period for the Product.

Yamanouchi further believes that U.S. Patent No. 6,017,927 is entitled to an extension of 2 years 327 days as determined by the following:

- (i) Number of days of the testing phase subsequent to issuance of the patent (January 25, 2000 to December 18, 2002) is 1059 days. The IND for the Product became effective on May 5, 1999, but U.S. Patent No. 6,017,927 issued on January 25, 2000.
- (ii) One half of the testing phase is 529 days.
- (iii) Number of days in the approval phase (December 19, 2002 to November 19, 2004) is 702 days.
- (iv) The sum of (ii) and (iii) is 1,231 days.
- (v) The patent was issued after the enactment date of 35 U.S.C. § 156, September 24, 1984, and the IND and NDA for the Product were filed subsequent to that date. Therefore, the term of the patent may only be extended for up to five years under 35 U.S.C. § 156(g)(1)(B) and 35 U.S.C. § 156(g)(6)(A).
- (vi) The patent term extension is also subject, under 35 USC 156(c)(3), to the fourteen year limitation as to the net effective life of the patent after the NDA approval. This limitation dictates that the subject patent cannot be extended beyond November 19, 2018. Adding 1,231 days to the term of the

patent remaining after the date of NDA approval of the Product exceeds fourteen years.

(vii) In light of the above, the extended expiration date of the subject patent is believed to be November 19, 2018, namely 2 years and 327 days after the date of the current patent term expiration (fourteen years after the date of NDA approval).

(13) **A STATEMENT THAT APPLICANT ACKNOWLEDGES A DUTY TO DISCLOSE TO THE COMMISSIONER OF PATENTS AND TRADEMARKS AND THE SECRETARY OF HEALTH AND HUMAN SERVICES OR THE SECRETARY OF AGRICULTURE ANY INFORMATION WHICH IS MATERIAL TO THE DETERMINATION OF ENTITLEMENT TO THE EXTENSION SOUGHT.**

Yamanouchi acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services any information that is material to any determinations to be made relative to this Application for Extension.

(14) **THE PRESCRIBED FEE FOR RECEIVING AND ACTING UPON THE APPLICATION FOR EXTENSION.**

Please charge deposit account number 194880 in the amount of \$1,120.00.

(15) **THE NAME, ADDRESS, AND TELEPHONE NUMBER OF THE PERSON TO WHOM INQUIRIES AND CORRESPONDENCE RELATING TO THE APPLICATION FOR PATENT TERM EXTENSION ARE TO BE DIRECTED.**

Inquiries and correspondence relating to this Application for Extension should be directed to:

Susan J. Mack
Sughrue Mion, PLLC
2100 Pennsylvania Ave., N.W.
Washington, D.C. 20037-3213
T: 202-293-7060
F: 202-293-7860
Email: smack@sughrue.com

(16) FOUR ADDITIONAL COPIES OF THE APPLICATION PAPERS

Four additional copies of the application are attached hereto as Attachment 4.

By:

Susan J. Mack

Susan J. Mack

Registration Number 30,951

Date: December 20, 2004

ATTACHMENT 1

Assignment

Whereas, I/We, Makoto TAKEUCHI, Ryo NAITO, Masahiko HAYAKAWA, Yoshinori OKAMOTO, Yasuhiro YONETOKU and Yasuo ISOMURA of Ibaraki, Japan and Ken IKEDA of Chiba, Japan

hereinafter called assignor(s), have invented certain improvements in
NOVEL QUINUCLIDINE DERIVATIVES AND
MEDICINAL COMPOSITION THEREOF

and executed an application for Letters Patent of the United States of America therefor on
July 28, 1997, and

Whereas, YAMANOUCHI PHARMACEUTICAL CO., LTD.
3-11, Nihonbashi-Honcho 2-chome, Chuo-ku, Tokyo 103 Japan

(assignee), desires to acquire the entire right, title, and interest in the application and invention, and to any United States patents to be obtained therefor;

Now therefore, for valuable consideration, receipt whereof is hereby acknowledged,

I/We, the above named assignor(s), hereby sell, assign and transfer to the above named assignee, its successors and assigns, the entire right, title and interest in the application and the invention disclosed therein for the United States of America, including the right to claim priority under 35 U.S.C. §119, and I/we request the Commissioner of Patents to issue any Letters Patent granted upon the invention set forth in the application to the assignee, its successors and assigns; and I/we will execute without further consideration all papers deemed necessary by the assignee in connection with the United States application when called upon to do so by the assignee.

I/We hereby authorize and request my attorneys SUGHRUE, MION, ZINN, MACPEAK & SEAS of 2100 Pennsylvania Avenue, N.W., Washington, D.C. 20037-3202 to insert here in parentheses (Application number 08/860,377, filed June 25, 1997) the filing date and application number of said application when known.

Date: July 28, 1997 s/ Makoto Takeuchi
Makoto TAKEUCHI

Date: July 28, 1997 s/ Ryo Naito
Ryo NAITO

Date: July 28, 1997 s/ Masahiko Hayakawa
Masahiko HAYAKAWA

Date: July 28, 1997 s/ Yoshinori Okamoto
Yoshinori OKAMOTO

Date: July 28, 1997 s/ Yasuhiro Yonetoku
Yasuhiro YONETOKU

Date: July 28, 1997 s/ Ken Ikeda
Ken IKEDA

ATTACHMENT 2



US006017927A

United States Patent [19]

Takeuchi et al.

[11] Patent Number: 6,017,927

[45] Date of Patent: Jan. 25, 2000

[54] QUINUCLIDINE DERIVATIVES AND MEDICINAL COMPOSITION THEREOF

[75] Inventors: Makoto Takeuchi; Ryo Naito; Masahiko Hayakawa; Yoshinori Okamoto; Yasuhiro Yonetoku, all of Ibaraki; Ken Ikeda, Chiba; Yasuo Isomura, Ibaraki, all of Japan

[73] Assignee: Yamanouchi Pharmaceutical Co., Ltd., Tokyo, Japan

[21] Appl. No.: 08/860,377

[22] PCT Filed: Dec. 27, 1995

[86] PCT No.: PCT/JP95/02713

§ 371 Date: Aug. 28, 1997

§ 102(e) Date: Aug. 28, 1997

[87] PCT Pub. No.: WO96/20194

PCT Pub. Date: Jul. 4, 1996

[30] Foreign Application Priority Data

Dec. 28, 1994 [JP] Japan 6-327045

[51] Int. Cl.⁷ A61K 31/435; C07D 453/02

[52] U.S. Cl. 514/305; 546/137

[58] Field of Search 546/137; 514/305

[56] References Cited

FOREIGN PATENT DOCUMENTS

A20309424 3/1989 European Pat. Off.

A1424021 4/1991 European Pat. Off.

A10247266 12/1997 European Pat. Off. .

7-06635 3/1995 Japan .

7258250 10/1995 Japan .

A2249093 4/1992 United Kingdom .


WO9206958 4/1992 WIPO .

WO9316048 8/1993 WIPO .

Primary Examiner—Patricia L. Morris
Attorney, Agent, or Firm—Sughrue, Mion, Zinn, Macpeak
& Seas, PLLC

[57] ABSTRACT

Quinuclidine derivatives represented by general following general formula (I), salts, N-oxides or quaternary ammonium salts thereof, and medicinal compositions containing the same.



The compound has an antagonistic effect on muscarinic M₃ receptors and is useful as a preventive or remedy for urologic diseases, respiratory diseases or digestive diseases.

7 Claims, No Drawings

QUINUCLIDINE DERIVATIVES AND
MEDICINAL COMPOSITION THEREOF

TECHNICAL FIELD


This invention relates to medicines, particularly quinuclidine derivatives or their salts, or quaternary ammonium salts having muscarinic receptor antagonistic activities and also to pharmaceutical compositions containing such compounds.

BACKGROUND ART

Studies have been made on the muscarinic receptor, and it is known that compounds having muscarinic receptor antagonistic activities cause bronchodilation, suppression of gastrointestinal motility, suppression of acid secretion, dry mouth, mydriasis, suppression of bladder contraction, hypohidrosis, tachycardia, or the like. It is known that the muscarinic receptor includes at least three subtypes. The M_1 receptor mainly exists in the brain or the like, the M_2 receptor in the heart or the like, and the M_3 receptor in the smooth muscles or gland tissues.

A number of such compounds having muscarinic receptor antagonistic activities are hitherto known and, for example, atropine is a typical example ("The MERCK INDEX, ELEVENTH EDITION", p. 138). However, atropine antagonizes the M_1 , M_2 and M_3 receptors non-selectively, so that it is difficult to use it for the treatment of a specific disease. In recent years, according to the progress of the studies on the subtypes of the muscarinic receptor, compounds having selective antagonistic activities against the M_1 , M_2 or M_3 receptor have been investigated (an unexamined published British Patent Application No. 2,249,093, an unexamined published Japanese Patent Application (kokai) 1-131145, and an unexamined published Japanese Patent Application (kokai) 3-133980). There is a demand for a compound having selective antagonistic activity against muscarinic M_3 receptor among these three subtypes and is free from the cardiac side effects resulting from the M_2 receptor.

The compound represented by the following general formula is described in an unexamined published Japanese Patent Application (kokai) 62-252764.




(wherein L represents NH or O;

X and Y each independently represents a hydrogen atom or a C_{1-6} alkyl group or they may be combined together to form a bond;

R_1 and R_2 each independently represents a hydrogen atom, a C_{1-6} alkyl group . . . (omission) . . . ;

R_3 and R_4 each independently represents a hydrogen atom, a halogen atom, CF_3 , a C_{1-6} alkyl group . . . (omission) . . . , a phenyl group, an amino group which may optionally be N-substituted by one or two groups selected from phenyl, C_{1-6} alkyl groups or may optionally be N-disubstituted by C_{6-8} polyethylene . . . (omission) . . . ;

5



p is 1 or 2; and q is 1-3.

The compound described in the above patent literature is disclosed as a 5-HT antagonist and no disclosure about the muscarinic receptor antagonistic activity is found. The above compound is clearly distinguished from the compound according to the present invention in pharmacological effects.

15

DISCLOSURE OF THE INVENTION

The inventors of the present application have carried out extensive studies on compounds having the above-described muscarinic M_3 receptor antagonistic activities. As a result, we created novel quinuclidine derivatives having a basic skeleton different from that of the conventional compound, and found that such compounds have excellent selective antagonistic activity against muscarinic M_3 receptor, resulting in the completion of the present invention.

Thus, the compounds of the present invention relate to quinuclidine derivatives represented by the following general formula (I); their salts, or quaternary ammonium salts; pharmaceutical compositions comprising said compounds or salts thereof and pharmaceutically acceptable carriers, particularly to muscarinic M_3 receptor antagonists.

20


30

35

40

45

(I)



(symbols in the formula have the following meanings:

Ring A: an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, wherein said ring may be substituted by an optional substituent;

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxycarbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1,

m: 0 or an integer of 1 to 3, and

50

55

60

65

n: an integer of 1 or 2, hereinafter the same apply similarly)

Among the compound (I) of the present invention, particularly preferred compounds are quinuclidine derivatives wherein the ring A represents an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, in which such a ring may be substituted by a substituent selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group, and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group, and their salts, or quaternary ammonium salts;

quinuclidine derivatives wherein R represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group, and the ring A represents an aryl group, a cycloalkyl group, a cycloalkenyl group, a 5- or 6-membered monocyclic heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, in which such a ring may be substituted by a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group, and their salts, or quaternary ammonium salts;

quinuclidine derivatives wherein m is 0, and the ring A represents an aryl group, a cycloalkyl group or a cycloalkenyl group which may be substituted by a halogen atom, a lower alkyl group, a hydroxyl group or a lower alkoxy group, or a 5- or 6-membered monocyclic heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, and their salts, or quaternary ammonium salts;

quinuclidine derivatives wherein the ring A represents a phenyl group which may be substituted by a halogen atom or a lower alkyl group, a cycloalkyl group, a pyridyl group, a furyl group or a thienyl group, and their salts, or quaternary ammonium salts;

quinuclidine derivatives wherein X represents a single bond, and their salts, or quaternary ammonium salts; and


quinuclidine derivatives wherein n is 2, and their salts, or quaternary ammonium salts.

The present invention also provides muscarinic M_3 receptor antagonists which comprise quinuclidine derivatives (I) or their salts, or quaternary ammonium salts, that is, the compound (I) of the present invention and pharmaceutically acceptable carriers, preferably agents for the prevention and/or treatment of urinary diseases (e.g., neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm and chronic cystitis), or respiratory

diseases (e.g., chronic obstructive pulmonary diseases, chronic bronchitis, asthma and rhinitis).

Hereinafter, the compound (I) of the present invention will be described in detail.

Different from the conventional muscarinic M_3 receptor antagonist, the compound (I) of the present invention is structurally characterized in that it has as a basic skeleton a tetrahydroisoquinoline skeleton (Ia) or isoindoline skeleton (Ib) having a quinuclidinyl carbonyl group, etc. bonded to the nitrogen atom in the ring as shown below.



Furthermore, the compound (I) of the present invention is characterized in that it has ring A, that is, a cyclic group selected from an aryl group, a cycloalkyl group, a cycloalkenyl group, a heteroaryl group having 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom or a 5- to 7-membered saturated heterocyclic group, at the 1-position of the tetrahydroisoquinoline or isoindoline through X.

Unless otherwise specified, the term "lower" as used in the definition of the general formula in this specification means a linear or branched carbon chain having 1 to 6 carbon atoms. Accordingly, the "lower alkyl group" means linear or branched alkyl group having 1 to 6 carbon atoms.

Specific examples include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, isopentyl, neopentyl, tert-pentyl, 1-methylbutyl, 2-methylbutyl, 1,2-dimethylpropyl, hexyl, isohexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl groups. Among these groups, alkyl groups having 1 to 4 carbon atoms such as methyl, ethyl, propyl, isopropyl and butyl groups are preferred, and a methyl group is more preferred.

The "aryl group" means aromatic hydrocarbon groups and preferably aryl groups having 6 to 14 carbon atoms. Specific examples include phenyl, naphthyl, indenyl, anthryl and phenanthryl groups, and a phenyl group is more preferred.

Examples of the "cycloalkyl group" include those having 3 to 8 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

Among these groups, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups are preferred, and a cyclohexyl group is more preferred.

Examples of the "cycloalkenyl group" include those having 3 to 8 carbon atoms such as 1-cyclopropenyl, 2-cyclopropenyl, 1-cyclobutenyl, 2-cyclobutenyl, 1-cyclopentenyl, 2-cyclopentenyl, 3-cyclopentenyl, 1-cyclohexenyl, 2-cyclohexenyl, 3-cyclohexenyl, 1-cycloheptenyl, 2-cycloheptenyl, 3-cycloheptenyl, 4-cycloheptenyl, 1-cyclooctenyl, 2-cyclooctenyl, 3-cyclooctenyl, 4-cyclooctenyl, 2,4-cyclopentadienyl, 2,5-cyclohexadienyl, 2,4-cycloheptadienyl, and 2,6-cycloheptadienyl.

The "heteroaryl group containing 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom" means a 5- or 6-membered heteroaryl group which may be condensed with a benzene ring. Specific examples include 5- or 6-membered monocyclic heteroaryl groups containing 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, such as furyl, thieryl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl and pyridazinyl groups; and 5- or 6-membered heteroaryl groups condensed with a benzene ring, such as indolyl, indazolyl, indolizinyl, quinolyl, quinazolinyl, quinolizinyl, quinoxalinyl, cinnolinyl, benzimidazolyl, benzofuranyl, dihydrobenzofuranyl, benzoisoxazolyl, benzoxazolyl, benzothiazolyl and benzothienyl groups.

Among these groups, preferred are 5- or 6-membered monocyclic heteroaryl groups containing 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom, and furyl, thieryl and pyridyl groups are more preferred.

The "5- to 7-membered saturated heterocyclic group" means a 5-, 6- or 7-membered saturated heterocyclic group containing 1 to 2 oxygen, nitrogen and/or sulfur atoms. Specific examples include pyrrolidinyl, imidazolidinyl, piperidinyl, piperazinyl and morpholinyl groups.

The "aryl group", "cycloalkyl group", "cycloalkenyl group", "heteroaryl group containing 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom", "5- or 6-membered monocyclic heteroaryl group containing 1 to 4 hetero atoms selected from the group consisting of an oxygen atom, a nitrogen atom and a sulfur atom", or "5- to 7-membered saturated heterocyclic group" as the group A may be substituted by an optional substituent. The number of the substituent is not limited to one but may be plural. Any group that can substitute for such a ring can be employed as the optional substituent. Preferred examples include a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group; a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group and a mono- or di-lower alkylamino group are more preferred; a halogen atom, a lower alkyl group, a

hydroxyl group and a lower alkoxy group are still more preferred; and a halogen atom and a lower alkyl group are particularly preferred.

Examples of the halogen atom include fluorine, chlorine, bromine and iodine. When the substituent is a halogen atom, the number of the substituents is not particularly limited. When two or more halogen atoms are substituted, any combination of the above atoms is possible. Examples of the halogen atom-substituted lower alkyl group include fluoromethyl, chloromethyl, bromomethyl, iodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 2-chloroethyl, 2-bromoethyl, dichloromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl and dichlorobromomethyl. Among these groups, a trifluoromethyl group is preferred.

Examples of the "lower alkoxy group" include methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, tert-butoxy, pentyloxy (amyloxy), isopentyloxy, tert-pentyloxy, neopentyloxy, 2-methylbutoxy, 1,2-dimethylpropoxy, 1-ethylpropoxy and hexyloxy. Among these groups, lower alkoxy groups containing an alkyl group having 1 to 4 carbon atoms, such as methoxy, ethoxy, propoxy and butoxy are preferred, and methoxy and ethoxy groups are more preferred.

Examples of the lower alkoxy carbonyl group include methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, isobutoxycarbonyl, sec-butoxycarbonyl, tert-butoxycarbonyl, pentyloxy (amyloxy) carbonyl, isopentyloxy carbonyl, tert-pentyloxy carbonyl, neopentyloxy carbonyl, 2-methylbutoxy carbonyl, 1,2-dimethylpropoxycarbonyl, 1-ethylpropoxycarbonyl and hexyloxy carbonyl.

Examples of the "lower acyl group" include formyl, acetyl, propionyl, butyryl, valeryl and pivaloyl, and formyl, acetyl and propionyl are preferred.

The "lower alkylthio group" means a mercapto group of which hydrogen atom has been substituted by the above-exemplified lower alkyl group, such as methylthio, ethylthio, propylthio, isopropylthio, butylthio, pentylthio and hexylthio groups.

Examples of the "lower alkylsulfonyl group" include methylsulfonyl, ethylsulfonyl, propylsulfonyl, isopropylsulfonyl, butylsulfonyl, pentylsulfonyl and hexylsulfonyl.

Examples of the "lower alkylsulfinyl group" include methylsulfinyl, ethylsulfinyl, propylsulfinyl, isopropylsulfinyl, butylsulfinyl, pentylsulfinyl and hexylsulfinyl.

Examples of the "lower alkanesulfonamido group" include methanesulfonamido, ethanesulfonamido, propanesulfonamido, isopropanesulfonamido, butanesulfonamido, pentanesulfonamido and hexanesulfonamido.

The "mono- or di-lower alkylcarbamoyl group" means a carbamoyl group in which one or two hydrogen atom(s) have been substituted by the above-exemplified lower alkyl group(s), such as methylcarbamoyl, ethylcarbamoyl, propylcarbamoyl and dimethylcarbamoyl groups.

The "mono- or di-lower alkylamino group" means an amino group in which one or two hydrogen atom(s) have been substituted by the above-exemplified lower alkyl group(s), such as methylamino, ethylamino, propylamino, dimethylamino, diethylamino and dipropylamino groups.

The term "lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group" means a lower alkyl group in which at least one optional

hydrogen atom has been substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group. The lower alkyl group substituted by a halogen atom is as described in the above description of the halogen atom.

The compound (I) of the present invention contains a quinuclidinyl group. The nitrogen atom of the quinuclidinyl group may form oxide (I=1) or quaternary ammonium salt. Where a quaternary ammonium salt is formed, specific examples of the group bound to the nitrogen atom include lower alkyl, lower alkenyl and lower alkynyl.

The term "lower alkenyl" as used herein means a linear or branched alkenyl group having 2 to 6 carbon atoms, such as vinyl, propenyl, butenyl, methylpropenyl, dimethylvinyl, pentenyl, methylbutenyl, dimethylpropenyl, ethylpropenyl, hexenyl, dimethylbutenyl and methylpentenyl. Among these groups, a propenyl group is preferred.

The "lower alkynyl group" means a linear or branched alkynyl group having 2 to 6 carbon atoms, such as ethynyl, propynyl, butynyl, methylpropynyl, pentynyl, methylbutynyl and hexynyl groups. Among these groups, alkynyl groups having 2 to 3 carbon atoms such as ethynyl and propynyl are preferred.

The anion for the quaternary ammonium salt is not particularly limited and the examples include ions of a halogen atom, triflate, tosylate and mesylate, preferably ions of a halogen atom, i.e. halide ions (e.g., chloride ion, bromide ion, iodide ion and triiodide ion). Examples of other anions include inorganic anions such as nitrate ion, sulfate ion, phosphate ion and carbonate ion, carboxylates such as formate (HCOO^-), acetate (CH_3COO^-), propionate, oxalate and malonate, and amino acid anions such as glutamate. Among the halide ions, bromide ion and iodide ion are preferred. Incidentally, the anion can be converted into a preferable anion as needed by the ordinary ion exchange reaction.


The compound (I) of the present invention contains an asymmetric carbon atom so that there exist optical isomers based on it. In addition, some of the invention compounds have stereoisomers or tautomers. The present invention also embraces diastereomers and enantiomers obtained by the separation of the above isomers as well as mixtures thereof.

Some of the compounds (I) of the present invention can form salts with an acid as well as the above-described quaternary ammonium salts with a quinuclidinyl group. Examples of such salt include acid addition salts with a mineral acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid or phosphoric acid; and those with an organic acid such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, citric acid, tartaric acid, carbonic acid, picric acid, methanesulfonic acid, ethanesulfonic acid or glutamic acid. The compounds (I) of the present invention also embrace hydrates, solvates with ethanol or the like, and substances in any polymorphism crystals.

(Preparation Process)

The compound (I) of the present invention can be prepared in accordance with various processes. The typical preparation processes are explained below.

First Preparation Method



(in the formula, Q^1 represents a leaving group which is advantageous in the present reaction, and ring A, R, X, m and n have the same meanings as defined above. Hereinafter, the same will apply similarly).


This reaction is carried out by stirring the compound represented by the general formula (II) and quinuclidinol represented by the general formula (III) in an amount corresponding to the reaction in an inert solvent at room temperature or under heating.

The leaving group Q^1 embraces, for example, a halogen atom, a lower alkoxy group, a phenoxy group and an imidazolyl group.

Examples of the inert solvent include dimethylformamide (DMF), dimethylacetamide, tetrahydrofuran (THF), dioxane, dimethoxyethane, diethoxyethane, benzene, toluene and xylene and mixed solvents thereof.

It is preferable to add a base (e.g., sodium, sodium hydride, sodium methoxide and sodium ethoxide) in order to accelerate the present reaction.

Second Preparation Method



(whence the ring A, R, X, m, n and Q^1 have the same meanings as defined above.)

This reaction is carried out by stirring the compound represented by the general formula (IV) and the compound

represented by the general formula (V) in the above-described inert solvent at room temperature or under heating.

It is preferable to add a base (e.g., sodium, sodium hydride, sodium methoxide, sodium ethoxide, triethylamine and pyridine) in order to accelerate the present reaction.

(Other Preparation Methods)

Among the compounds of the present invention, a compound in which the nitrogen atom of the quinuclidinyl group forms oxide or a quaternary ammonium salt can be prepared by N-oxide formation or N-alkylation of a tertiary amine compound in the compounds of the present invention.

The N-oxide formation reaction can be carried out by the oxidation reaction in a conventional manner, more specifically, by stirring a tertiary amine compound in the compounds of the present invention and a corresponding amount or excess amount of oxidizing agent in an inert solvent such as chloroform, dichloromethane or dichloroethane, an alcohol such as methanol or ethanol or water or a mixed solvent thereof under cooling or at room temperature, or in some cases under heating. Examples of the oxidizing agent include organic peracids such as m-chloroperbenzoic acid, sodium periodate and hydrogen peroxide.

The N-alkylation reaction can be carried out in accordance with the conventional N-alkylation reaction, more specifically by stirring a tertiary amine compound in the compound of the present invention and a corresponding amount of an alkylating agent in an inert solvent such as dimethylformamide, chloroform, benzene, 2-butanone, acetone or tetrahydrofuran under cooling or a room temperature, or in some cases under heating.

Examples of the alkylating agent include lower alkyl halides, lower alkyl trifluoromethanesulfonates, lower alkyl p-toluenesulfonates and lower alkyl methanesulfonates, preferably lower alkyl halides.

For the preparation of the compound of the present invention, it is sometimes necessary to protect a functional group. In such a case, introduction of a proper protecting group and deprotection operation in a conventional manner are carried out additionally.

The compound of the present invention so prepared is provided as is in the free form, or after subjected to the salt formation treatment in a conventional manner, it is isolated and purified as its salt. Isolation and purification are carried out by the ordinary chemical operation such as extraction, concentration, evaporation, crystallization, filtration, recrystallization or a variety of chromatography.

Industrial Applicability

The compound of the present invention has affinity and selectivity for the muscarinic M_3 receptor and, as an M_3 receptor antagonist, it is useful as an agent for prevention or treatment of various M_3 receptor-related diseases, particularly urinary diseases such as urinary incontinence or pollakiuria in neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, unstable bladder, cystospasm or chronic cystitis; respiratory diseases such as chronic obstructive pulmonary diseases, chronic bronchitis, asthma or rhinitis; or digestive diseases such as irritable bowel syndrome, spastic colitis or diverticulitis.

In particular, the compound of the present invention has high selectivity for the M_3 receptor existing in the smooth muscle or gland tissues compared with the M_2 receptor existing in the heart or the like, so that it has high utility as an M_3 receptor antagonist having less side effects on the heart or the like, particularly as an agent for prevention or

treatment of urinary incontinence, pollakiuria, chronic obstructive pulmonary diseases, chronic bronchitis, asthma or rhinitis.

The affinity and antagonism of the compound of the present invention for the muscarinic receptor was confirmed by the following tests.

Muscarinic Receptor Binding Test (in vitro)

a. Preparation of Membranes

From a male Wistar rat (Japan SLC), the heart and submandibular gland were excised, mixed with a 20 mM HEPES buffer (pH 7.5, which will hereinafter be abbreviated as "HEPES buffer") containing 5 times the volume of 100 mM sodium chloride and 10 mM magnesium chloride was added, followed by homogenization under ice-cooling. The resulting mixture was filtered through gauze, followed by ultracentrifugation at 50,000 \times g and 4° C. for 10 minutes. The precipitate obtained was suspended in an HEPES buffer, followed by further ultracentrifugation at 50,000 \times g and 4° C. for 10 minutes. The precipitate obtained was suspended in an HEPES buffer. The resulting suspension was stored at -80° C. and provided for the test after melting upon use.

b. Muscarinic M_2 Receptor Binding Test

The test was carried out in accordance with the method of Doods et al. (*J. Pharmacol. Exp. Ther.*, 242, 257-262, 1987) with some modifications. The cardiac membrane sample,

[3 H]-quinuclidinyl benzilate and the test compound were incubated in a 0.5 ml HEPES buffer at 25° C. for 45 minutes, followed by suction filtration through a glass filter (Whatman GF/B). The filter was washed three times with 5 ml portions of an HEPES buffer. The radioactivity of the [3 H]-quinuclidinyl benzilate adsorbed on the filter was measured by a liquid scintillation counter. Incidentally, nonspecific binding of the receptor was determined by the addition of 1 μ M atropine. The binding of the compound of the present invention for the muscarinic M_2 receptor was determined from a dissociation constant (K_i) calculated, in accordance with Chen and Prusoff (*Biochem. Pharmacol.* 22, 3099, 1973), based on the concentration (IC₅₀) of the test compound at which 50% of the binding of the [3 H]-quinuclidinyl benzilate, that is, a labeled ligand was inhibited.

c. Muscarinic M_3 Receptor Binding Test

In a similar manner to the above muscarinic M_2 receptor binding test except that the submandibular gland was used as a membrane sample and [3 H]-N-methylscopolamine was used as a labeled ligand, a muscarinic M_3 receptor binding test was carried out.

Results: The compound (I) of the present invention had a K_i value of from 10⁻⁸ to 10⁻¹⁰ for M_3 receptor, which suggested that the affinity for M_3 receptor was at least 10 times as high as that for M_2 receptor.

50 Muscarinic Receptor Antagonism Test (in vivo)

a. Test on Rhythmic Bladder Contraction in Rat

A female Wistar rat (130-200 g) was subjected to urethane anesthesia (1.0 g/kg s.c.), followed by ligation of the ureter on the kidney side. A urethral catheter was allowed to remain in the bladder, and about 1.0 ml of physiological saline was injected into the bladder through the catheter to cause rhythmic bladder contraction. Intravesical pressure was measured by a pressure transducer. After rhythmic contraction continued stable for at least 5 minutes, the test compound was cumulatively administered from the external jugular vein. Five to ten minutes later, the intravesical pressure was measured. An inhibition ratio of bladder contraction was determined compared with the bladder contraction before administration of the test compound and the dose of the test compound required for 30% inhibition of the bladder contraction before administration was designated as ED₃₀.

As a result of the test, the compound of the present invention showed good ED_{50} value.

b. Test on Salivary Secretion in Rat

A male Wistar rat (160–190 g) was subjected to anesthesia with urethane (0.8 g/kg i.p.), and the test compound was administered (to the control group: solvent). Fifteen minutes later, 0.8 μ mol/kg of oxotremorine was administered. In each case, the drug was administered through its femoral artery. The saliva secreted for 5 minutes after the administration of oxotremorine was collected and weighed. The inhibition ratio against the amount of saliva in the control group was determined and the dose of the test compound required for 50% inhibition of the amount of saliva in the control group was designated as ID_{50} .

As a result of the test, the ID_{50} value of atropine tested as a comparative compound was substantially the same with the ED_{50} value obtained in the above rat rhythmical bladder contraction test, while the ID_{50} value of the invention compound was at least 5 times as much as the above-described ED_{50} value, which suggested that the compound of the present invention has relatively weak action against the salivary secretion.

c. Test on Bradycardia in Rat

The test was carried out in accordance with the method of Doods et al. (*J. Pharmacol. Exp. Ther.*, 242, 257–262, 1987). A male Wistar rat (250–350 g) was subjected to anesthesia with pentobarbital sodium (50 mg/kg i.p.). The neck region was excised, followed by the division of right and left vagus nerves. After a cannula was inserted into a trachea to secure airway, a stainless rod was inserted from the orbit and the spinal cord was destroyed. Under artificial respiration (at 10 cc/kg and 50 times/minute), the rectal temperature was maintained at 37.5° C. and a heart rate was monitored at the common carotid artery. An indwelling needle was fixed to the femoral artery, from which the drug was administered. After the destruction of the spinal cord, the rat was allowed to stand for 15 minutes to attain the equilibrium, followed by the administration of atenolol (10 mg/kg). After the equilibration for additional 15 minutes, the test compound was administered. Fifteen minutes later, oxotremorine was cumulatively administered, thereby the reduction in the heart rate was measured. The amount of the test compound required for 10-times rightward shift of the dose-response curve of the control group was designated as DR_{10} .

Results: The compound (I) of the present invention had sufficiently low activity against bradycardia and no bradycardia was observed at the administration amount of several mg/kg.

As a result of the above-described muscarinic receptor binding test (*in vitro*), it was found that the compound (I) of the present invention had selectivity and high affinity for M_3 receptor. Even in the muscarinic receptor antagonism test (*in vivo*), the compound of the present invention showed good muscarinic M_3 antagonistic activity but low activity on the bradycardia having relationship with muscarinic M_2 receptor. Accordingly, it was found that the compound (I) of the present invention has selective antagonistic activity against muscarinic M_3 receptor, and furthermore, it has less side effects such as dry mouth compared with the conventional anti-cholinergic agent.

A pharmaceutical composition containing one or more of the compounds of the present invention and salts thereof is prepared using an ordinary pharmaceutically acceptable carrier.

In the present invention, the administration of the pharmaceutical composition can be carried out either orally or

parenterally in the form of an injection, suppository, transdermal agent, inhalant or intravesical injection.

The dose is optionally determined in each case in consideration of the conditions, age, sex and the like of the patient to be administered. In the oral administration, the daily dose may generally range from about 0.01 mg/kg to 100 mg/kg per adult. It is administered once or in 2–4 portions. Where intravenous administration is adopted in consideration of the conditions of the patient, the daily dose may generally range from about 0.001 mg/kg to 10 mg/kg per adult, once or plural portions per day.

Examples of the pharmaceutical carrier include nontoxic solid or liquid pharmaceutical substances.

Examples of the solid composition for the oral administration include tablets, pills, capsules, powders and granules, or the like. In such solid compositions, one or more active substances are mixed with at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, agar, pectin, magnesium metasilicate or magnesium aluminate. In the composition, it is possible to incorporate additives other than the above inert diluent, for example, a lubricant such as magnesium stearate, a disintegrator such as cellulose calcium glycolate, a stabilizer such as lactose, a solubilization aid such as glutamic acid or aspartic acid in a conventional manner. A tablet or pill may optionally be coated with sugar or a film of a gastric or enteric substance such as sucrose, gelatin, hydroxypropylcellulose or hydroxypropylmethylcellulose phthalate.

Examples of the liquid composition for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups and elixirs which contain a commonly employed inert diluent such as purified water or ethanol. The composition can also contain, in addition to such an inert diluent, a wetting agent, auxiliary agent such as suspending agent, sweetener, flavoring agent, aroma and/or antiseptic.

The injection for parenteral administration according to the present invention include a sterile aqueous or nonaqueous solution, suspension or emulsion. Examples of the aqueous solution and suspension include distilled water and physiological saline for injection. Examples of the non-water-soluble solution or suspension include ethylene glycol, polypropylene glycol, polyethylene glycol, vegetable oils such as cacao butter, olive oil or sesame oil, alcohols such as ethanol, gum arabic and "Polysolvate 80" (trade name). Such a composition may further contain an isotonicity agent, antiseptic agent, wetting agent, emulsifying agent, dispersing agent, stabilizer (for example, lactose) and/or solubilizing aid (for example, glutamic acid, aspartic acid). They are sterilized by, for example, filtration through a bacteria-retaining filter, incorporation of a sterilizer, or irradiation. Alternatively, a sterile solid composition which has been prepared in advance is dissolved in sterile water or a sterile injection solvent upon use.

BEST MODES FOR CARRYING OUT THE INVENTION

The present invention will hereinafter be described in further detail with reference to the following Examples. However, the compounds of the present invention should not be construed as being limited to the compounds which will be described later in Examples but embrace all the compounds represented by the above formula (I) and salts, hydrates, solvates, geometrical and optical isomers and any polymorphism forms of the compound (I).

Incidentally, the starting compounds for the compound of the present invention include novel compounds and prepa-

13

ration examples of such starting compounds will be described below as Reference Examples.

REFERENCE EXAMPLE 1

To a 130 ml dichloromethane solution containing 6.28 g of 1-phenyl-1,2,3,4-tetrahydroisoquinoline and 3.34 g of triethylamine, 3.1 ml of ethyl chloroformate was added dropwise under ice-cooling, followed by stirring at room temperature overnight. The reaction solution was washed successively with water, 1N hydrochloric acid, water and brine and then dried over anhydrous sodium sulfate. The solvent was removed under reduced pressure, thereby 10.58 g of ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate was obtained as pale yellow oil.

Infrared absorption spectrum $\nu_{\text{max}}(\text{neat})\text{cm}^{-1}$: 1700, 1430, 1296, 1230, 1122. Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.29 (3H, t, $J=7.3$ Hz), 2.75–3.45 (3H, m), 3.90–4.40 (1H, m), 4.21 (2H, q, $J=7.3$ Hz), 6.38 (1H, s), 6.95–7.45 (9H, m).

In a similar manner to Reference Example 1, the compounds of the following Reference Examples 2 to 14 were obtained.

REFERENCE EXAMPLE 2

Methyl 1-phenyl-2-isoquinolinecarboxylate

Starting compounds: 1-phenylisoindoline, methyl chloroformate

Infrared absorption spectrum $\nu_{\text{max}}(\text{KBr})\text{cm}^{-1}$: 1708, 1460, 1376, 1100. Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 3.60, 3.72 (3H, sx 2), 4.89, 4.96 (2H, sx 2), 5.94, 6.03 (1H, sx 2), 6.95–7.10 (1H, m), 7.15–7.35 (8H, m).

REFERENCE EXAMPLE 3

Ethyl 1-(4-pyridyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-(4-pyridyl)-1,2,3,4-tetrahydroisoquinoline

Properties: pale yellow oil

Mass analysis (m/z, EI): 282 (M $^+$); Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.29 (3H, t, $J=7.1$ Hz), 2.60–3.45 (3H, m), 3.85–4.20 (1H, m), 4.22 (2H, q, $J=7.1$ Hz), 6.31 (1H, s), 7.14 (2H, dd, $J=4.4, 1.5$ Hz), 7.17–7.26 (4H, m), 8.51 (2H, dd, $J=4.4, 1.5$ Hz)

REFERENCE EXAMPLE 4

Ethyl 1,2,3,4-tetrahydro-1-(2-thienyl)-2-isoquinolinecarboxylate

Starting compound: 1,2,3,4-tetrahydro-1-(2-thienyl)isoquinoline

Properties: pale yellow oil

Mass analysis (m/z, EI): 287 (M $^+$); Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.32 (3H, t, $J=7.3$ Hz), 2.65–3.60 (3H, m), 4.00–4.30 (1H, m), 4.23 (2H, q, $J=7.3$ Hz), 6.53 (1H, s), 6.70–6.95 (2H, m), 7.15–7.30 (5H, m)

REFERENCE EXAMPLE 5

Ethyl 1,2,3,4-tetrahydro-1-(3-thienyl)-2-isoquinolinecarboxylate

Starting compound: 1,2,3,4-tetrahydro-1-(3-thienyl)-isoquinoline

Properties: Orange oil

14

Mass analysis (m/z, FAB): 288 (M $^+$ +1); Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.2–1.3 (3H, m), 2.7–2.8 (1H, m), 2.9–3.0 (1H, m), 3.1–3.3 (1H, m), 3.9–4.2 (3H, m), 6.2–6.4 (1H, m), 6.83 (1H, s), 6.95–7.26 (6H, m)

REFERENCE EXAMPLE 6

Ethyl 1-(2-furyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-(2-furyl)-1,2,3,4-tetrahydroisoquinoline

Mass analysis (m/z, EI): 271 (M $^+$); Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.30 (3H, t, $J=6.5$ Hz), 2.75–2.85 (1H, m), 2.90–3.10 (1H, m), 3.20–3.50 (1H, m), 4.05–4.35 (4H, m), 6.00 (1H, s), 6.20–6.45 (2H, m), 7.15–7.25 (4H, m), 7.33 (1H, s)

REFERENCE EXAMPLE 7

(1R)-Ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline

Elemental analysis (for $\text{C}_{18}\text{H}_{19}\text{NO}_2$);

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 76.84 | 6.81 | 4.98 |
| Found: | 76.53 | 6.82 | 4.93 |

35 Specific optical rotation $[\alpha]_D^{25}$: 199.2 (C=1.03, CHCl_3)
Mass analysis (m/z, FAB): 282 (M $^+$ +1)

REFERENCE EXAMPLE 8

(1S)-Ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: (1S)-1-phenyl-1,2,3,4-tetrahydroisoquinoline

Elemental analysis (for $\text{C}_{18}\text{H}_{19}\text{NO}_2$);

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 76.84 | 6.81 | 4.98 |
| Found: | 76.64 | 6.82 | 4.99 |

Specific optical rotation $[\alpha]_D^{25}$: -200.9 (C=1.09, CHCl_3)
Mass analysis (m/z, EI): 281 (M $^+$)

REFERENCE EXAMPLE 9

Ethyl 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-(4-chlorophenyl)-1,2,3,4-tetrahydroisoquinoline

Properties: Pale yellow oil

Mass analysis (m/z, EI): 315 (M $^+$); Nuclear magnetic resonance spectrum (CDCl_3 , TMS internal standard); δ : 1.29 (3H, t, $J=7.0$ Hz), 2.70–3.52 (3H, m), 4.00–4.30 (1H, m), 4.20 (2H, q, $J=7.0$ Hz), 6.35 (1H, s), 7.05–7.35 (8H, m)

15

REFERENCE EXAMPLE 10

Ethyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-(4-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline

Properties: Pale yellow oil

Mass analysis (m/z, FAB): 300 (M^++1); Nuclear magnetic resonance spectrum ($CDCl_3$, TMS internal standard); δ : 1.30 (3H, t, $J=8.9$ Hz), 2.75 (1H, dd, $J=12.5, 3.4$ Hz), 2.9-3.1 (1H, m), 3.1-3.3 (1H, m), 4.0-4.3 (3H, m), 6.2-6.4 (1H, m), 6.93-7.03 (3H, m), 7.16-7.24 (5H, m).

REFERENCE EXAMPLE 11

Ethyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate

Starting compound: 1,2,3,4-tetrahydro-1-(4-tolyl)isoquinoline

Mass analysis (m/z, EI): 295 (M^+); Nuclear magnetic resonance spectrum ($CDCl_3$, TMS internal standard); δ : 1.20-1.35 (3H, m), 2.30 (3H, s), 2.70-2.80 (1H, m), 2.90-3.10 (1H, m), 3.23 (1H, t, $J=10.0$ Hz), 3.95-4.30 (3H, m), 6.29, 6.41 (1H, brs $\times 2$), 7.00-7.25 (8H, m).

REFERENCE EXAMPLE 12

Ethyl 1-benzyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-benzyl-1,2,3,4-tetrahydroisoquinoline

Properties: Pale yellow oil

Mass analysis (m/z, FAB): 296 (M^++1); Nuclear magnetic resonance spectrum ($CDCl_3$, TMS internal standard); δ : 1.02, 1.23 (3H, t $\times 2$, $J=7.1$ Hz), 2.63-3.20 (4H, m), 3.30-3.50 (1H, m), 3.75-4.25 (3H, m), 5.27, 5.38 (1H, t $\times 2$, $J=6.8$ Hz), 6.85-7.28 (9H, m).

REFERENCE EXAMPLE 13

Ethyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-cyclohexyl-1,2,3,4-tetrahydroisoquinoline

Properties: yellow oil

16

Mass analysis (m/z, FAB): 288 (M^++1); Nuclear magnetic resonance spectrum ($CDCl_3$, TMS internal standard); δ : 0.70-2.00 (11H, m), 1.26 (3H, t, $J=7.3$ Hz), 2.89 (2H, t, $J=7.1$ Hz), 3.25-4.20 (2H, m), 4.14 (2H, q, $J=7.1$ Hz), 4.65-4.95 (1H, m), 7.00-7.30 (4H, m).

REFERENCE EXAMPLE 14

Ethyl 1-(3-furyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

Starting compound: 1-(3-furyl)-1,2,3,4-tetrahydroisoquinoline

Properties: yellow oil

Mass analysis (m/z, EI): 271 (M^+); Nuclear magnetic resonance spectrum ($CDCl_3$, TMS internal standard); δ : 1.31 (3H, t, $J=7.0$ Hz), 2.55-3.40 (3H, m), 3.90-4.30 (1H, m), 4.22 (2H, q, $J=7.0$ Hz), 6.20-6.45 (2H, m), 6.95-7.40 (6H, m).

The chemical structural formulas of the compounds obtained in Reference Examples 1-14 are shown in the following Tables 1-2.

TABLE 1

| Reference Example No. | Structural Formula | Reference Example No. | Structural Formula |
|-----------------------|--------------------|-----------------------|--------------------|
| 1 | | 6 | |
| 2 | | 7 | |

6,017,927

17

18

TABLE 1-continued

| Reference Example No. | Structural Formula | Reference Example No. | Structural Formula |
|-----------------------|--------------------|-----------------------|--------------------|
| 3 | | 8 | |
| 4 | | 9 | |
| 5 | | 10 | |

TABLE 2-continued

45

TABLE 3



| Reference Example No. | Structural Formula | |
|-----------------------------|---|-------------|
| 11 |  | 5 6 6 |

TABLE 2-continued

14



EXAMPLE 1

To a 30 ml toluene solution containing 0.70 g of ethyl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate and 0.41 g of 3-quinuclidinol, 0.03 g of sodium hydride (60%) was added. The resulting mixture was stirred at 140° C. for 2 days while removing the ethanol formed. The reaction mixture was cooled to room temperature, brine was added, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The resulting residue was purified by silica gel column chromatography (chloroform:methanol = 10:1 → chloroform:methanol:28% aqueous ammonia = 10:1:0.1), thereby 0.11 g of 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate was obtained as yellow oil. The resulting oil was dissolved in 10 ml of ethanol, followed by the addition of 27 mg of oxalic acid. Then, the solvent was removed under reduced pressure. The resulting solid was recrystallized from isopropanol and isopropyl ether, thereby 0.08 g of 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monooxalate was obtained as colorless crystals.

Melting point: 122–124° C. (i-PrOH-i-Pr₂O)
Elemental analysis (for C₂₅H₂₈N₂O₆·0.75H₂O)

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 64.43 | 6.38 | 6.01 |
| Found: | 64.25 | 6.15 | 5.88 |

In a similar manner to Example 1, the compound of Example 2 was obtained.

EXAMPLE 2

3-Quinuclidinyl 1-phenyl-2-isoindolinecarboxylate monohydrochloride
Starting compound: methyl 1-phenyl-2-isoindolinecarboxylate
Melting point: 164–165° C. (EtOH-Et₂O)
Elemental analysis (for C₂₂H₂₅N₂O₂Cl·1.75H₂O)

| | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 63.45 | 6.90 | 6.73 | 8.51 |
| Found: | 63.54 | 6.59 | 6.76 | 8.12 |

EXAMPLE 3

To a 50 ml toluene suspension containing 720 mg of ethyl 1-(4-pyridyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate and 973 mg of 3-quinuclidinol, 102 mg of sodium hydride

(60%) was added at room temperature. The resulting mixture was heated under reflux for 5 hours and 40 minutes while the resulting ethanol was removed together with toluene. The reaction mixture was cooled to room temperature, followed by addition of 20 ml of water. The resulting mixture was extracted with chloroform. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and then concentrated under reduced pressure.

The resulting residue was purified by silica gel column chromatography (chloroform:methanol:28% aqueous ammonia=100:2:1), thereby 827 mg of 3-quinuclidinyl 1-(4-pyridyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate were obtained as yellow oil. The resulting oil was dissolved in 5 ml of ethyl acetate, 2 ml of a 4N hydrogen chloride in ethyl acetate solution was added. The solvent was then removed under reduced pressure. Ethanol and ether were added to the residue, and the crude crystals thus obtained was recrystallized from ethanol and ether, thereby 402 mg of 3-quinuclidinyl 1-(4-pyridyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate dihydrochloride was obtained as pale yellow crystals.

Melting point: 167–169° C. (EtOH-Et₂O)

Elemental analysis (for C₂₂H₂₇N₃O₂Cl₂·2.2H₂O)

| | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 55.51 | 6.65 | 8.83 | 14.90 |
| Found: | 55.46 | 6.98 | 8.64 | 14.84 |

In a similar manner to Example 3, the compounds of Examples 4 to 6 which will be described below were obtained.

EXAMPLE 4

3-Quinuclidinyl 1,2,3,4-tetrahydro-1-(2-thienyl)-2-isoquinolinecarboxylate monooxalate
Starting compound: Ethyl 1,2,3,4-tetrahydro-1-(2-thienyl)-2-isoquinolinecarboxylate
Elemental analysis (for C₂₃H₂₆N₂O₆S·1.3H₂O);

| | C (%) | H (%) | N (%) | S (%) |
|---------|-------|-------|-------|-------|
| Calcd.: | 57.32 | 5.98 | 5.81 | 6.65 |
| Found: | 57.62 | 6.00 | 5.84 | 6.27 |

Mass analysis (m/z, FAB): 369 (M⁺+1)

EXAMPLE 5

(1RS,3'R)-3'-Quinuclidinyl 1,2,3,4-tetrahydro-1-(3-thienyl)-2-isoquinolinecarboxylate
Starting compounds: ethyl 1,2,3,4-tetrahydro-1-(3-thienyl)-2-isoquinolinecarboxylate, (3R)-3-quinuclidinol
Properties: Brown oil
Elemental analysis (for C₂₁H₂₄N₂O₂S·0.3H₂O);

| | C (%) | H (%) | N (%) | S (%) |
|---------|-------|-------|-------|-------|
| Calcd.: | 67.46 | 6.63 | 7.49 | 8.58 |
| Found: | 67.35 | 6.76 | 7.21 | 8.46 |

Mass analysis (m/z, FAB): 369 (M⁺+1)

EXAMPLE 6

3-Quinuclidinyl 1-(2-furyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Starting compound: ethyl 1-(2-furyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate

21

Properties: Pale yellow oil

Elemental analysis (for $C_{21}H_{24}N_2O_3.0.5H_2O$);

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 69.79 | 6.97 | 7.75 |
| Found: | 70.03 | 7.05 | 7.44 |

Mass analysis (m/z, FAB): 353 (M^++1)

EXAMPLE 7

To a 30 ml pyridine solution containing 2.09 g of (1R)-1-phenyl-1,2,3,4-tetrahydroisoquinoline, 2.26 g of 3-quinuclidinyl chloroformate monohydrochloride was added at room temperature, followed by stirring at 80° C. for 4 hours. Then, 0.12 g of 3-quinuclidinyl chloroformate monohydrochloride, followed by stirring at 80° C. for 4 hours. Then, 1.01 g of 3-quinuclidinyl chloroformate monohydrochloride was added, and the mixture was stirring at 80° C. for 25 hours. The reaction mixture was concentrated under reduced pressure. Water was added to the residue, followed by washing with ethyl acetate twice. The resulting aqueous layer was adjusted to pH 9 with saturated sodium hydrogencarbonate aqueous solution, followed by extraction with ethyl acetate. After the organic layer was dried over anhydrous sodium sulfate, the solvent was removed under reduced pressure, thereby 3.02 g of (1R,3'RS)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate was obtained as yellow oil.

Mass analysis (m/z, FAB): 363 (M^++1); Nuclear magnetic resonance spectrum (DMSO-d₆, TMS internal standard); δ: 1.20–2.00 (5H, m), 2.40–2.95 (6H, m), 3.00–3.60 (3H, m), 3.80–3.95 (1H, m), 4.55–4.70 (1H, m), 6.25 (1H, brs), 7.05–7.35 (10H, m).

EXAMPLE 8

To a 120 ml toluene suspension containing 12.0 g of (1R)-ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate and 16.27 g of (3R)-3-quinuclidinol, 1.69 g of sodium hydride (60%) was added at room temperature. The resulting mixture was heated for 3 hours while the resulting ethanol was removed together with toluene. The reaction mixture was cooled to room temperature, and 50 ml of brine was added, followed by extraction with ethyl acetate. The organic layer was washed with water and then extracted with 20% hydrochloric acid. The resulting aqueous layer was adjusted to pH 9 to 10 by adding a 1N aqueous solution of sodium hydroxide, followed by extraction with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and then concentrated under reduced pressure. The residue was dissolved in 140 ml of ethanol, and 10 ml of a 4N hydrogen chloride in ethyl acetate solution was added to the resulting solution. The solvent was then removed under reduced pressure. Acetonitrile and ether were added to the residue, and the resulting crude crystals were recrystallized from acetonitrile and ether, thereby 10.1 g of (1R,3'R)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monohydrochloride was obtained as colorless crystals.

22

Melting point: 212–214° C. (CH_3CN-Et_2O)Elemental analysis (for $C_{23}H_{27}N_2O_2Cl$);

| 5 | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 69.25 | 6.82 | 7.02 | 8.89 |
| Found: | 69.24 | 6.89 | 7.03 | 8.97 |

10 Specific optical rotation $[\alpha]_D^{25}$: 98.1 (C=1.00, EtOH)

In a similar manner to Example 8, the compounds of the following Examples 9 to 16 were obtained.

EXAMPLE 9

(1S,3'S)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monohydrochloride

Starting compounds: (1S)-ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, (3S)-3-quinuclidinol Melting point: 211–212° C. ($EtOH-Et_2O$)Elemental analysis (for $C_{23}H_{27}N_2O_2Cl.0.25H_2O$);

| 25 | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 68.48 | 6.87 | 6.94 | 8.79 |
| Found: | 68.32 | 6.75 | 6.94 | 8.94 |

30 Specific optical rotation $[\alpha]_D^{25}$: -97.4 (C=0.50, EtOH)

EXAMPLE 10

(1S,3'R)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monohydrochloride

Starting compounds: (1S)-ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, (3R)-3-quinuclidinol Melting point: 195–196° C. ($EtOH-Et_2O$)Elemental analysis (for $C_{23}H_{27}N_2O_2Cl.0.25H_2O$);

| 45 | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 68.48 | 6.87 | 6.94 | 8.79 |
| Found: | 68.73 | 6.88 | 6.95 | 8.70 |

Specific optical rotation $[\alpha]_D^{25}$: -151.2 (C=0.50, EtOH)

EXAMPLE 11

(1R,3'S)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monohydrochloride

Starting compounds: (1R)-ethyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, (3S)-3-quinuclidinol Melting point: 194–195° C. (CH_3CN-Et_2O)Elemental analysis (for $C_{23}H_{27}N_2O_2Cl$);

| 60 | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 69.25 | 6.82 | 7.02 | 8.89 |
| Found: | 69.08 | 6.71 | 6.99 | 8.91 |

65 Specific optical rotation $[\alpha]_D^{25}$: 163.2 (C=0.50, EtOH)

23
EXAMPLE 12

3-quinuclidinyl 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate monofumarate
Starting compounds: 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Melting point: 164–166° C. (EtOH-Et₂O)
Elemental analysis (for C₂₇H₂₉N₂O₆Cl·0.5H₂O);

| | C (%) | H (%) | N (%) | Cl (%) |
|---------|-------|-------|-------|--------|
| Calcd.: | 62.13 | 5.79 | 5.37 | 6.79 |
| Found: | 62.19 | 5.68 | 5.23 | 6.49 |

EXAMPLE 13

(1RS,3'R)-3'-quinuclidinyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Starting compounds: ethyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, (3R)-3-quinuclidinol
Properties: colorless oil
Elemental analysis (for C₂₃H₂₅N₂O₂F·0.1H₂O);

| | C (%) | H (%) | N (%) | F (%) |
|---------|-------|-------|-------|-------|
| Calcd.: | 72.27 | 6.64 | 7.33 | 4.97 |
| Found: | 72.05 | 6.63 | 7.15 | 4.99 |

Mass analysis (m/z, FAB): 381 (M⁺+1)

EXAMPLE 14

3-quinuclidinyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate
Starting compounds: ethyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate
Properties: colorless oil
Elemental analysis (for C₂₄H₂₈N₂O₂·0.8H₂O);

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 73.74 | 7.63 | 7.17 |
| Found: | 73.96 | 7.50 | 6.95 |

Mass analysis (m/z, FAB): 377 (M⁺+1)

EXAMPLE 15

3-Quinuclidinyl 1-benzyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Starting compound: ethyl 1-benzyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Properties: pale yellow oil
Elemental analysis (for C₂₄H₂₈N₂O₂·0.5H₂O);

| | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 74.78 | 7.58 | 7.26 |
| Found: | 74.95 | 7.83 | 7.18 |

Mass analysis (m/z, FAB): 377 (M⁺+1)

24
EXAMPLE 16

3-Quinuclidinyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Starting compounds: ethyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate
Properties: pale yellow amorphous
Elemental analysis (for C₂₃H₃₂N₂O₂·0.3H₂O);

| 10 | C (%) | H (%) | N (%) |
|---------|-------|-------|-------|
| Calcd.: | 73.88 | 8.79 | 7.49 |
| Found: | 73.76 | 8.75 | 7.37 |

15 Mass analysis (m/z, FAB): 369 (M⁺+1)

EXAMPLE 17

In 12 ml of dichloromethane, 1.20 g of (1R,3'R)-3'-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate was dissolved, 0.33 g of sodium hydrogencarbonate and 0.79 g of m-chloroperbenzoic acid (80%) were added under ice-cooling, followed by stirring at room temperature for one hour. Water was added to the reaction mixture and then the mixture was extracted with dichloromethane. The organic layer was washed with an aqueous solution of sodium thiosulfate and then dried over anhydrous magnesium sulfate. The solvent was then removed under reduced pressure, and the residue was purified by silica gel column chromatography (chloroform:methanol=20:1), thereby 0.43 g of (1'R,3R)-3-[(1'-phenyl-1', 2',3',4'-tetrahydro-2'-isoquinolyl)carbonyl]oxy]quinuclidine 1-oxide was obtained.
Properties: white amorphous

Mass analysis (m/z, FAB): 379 (M⁺+1); Nuclear magnetic resonance spectrum (CDCl₃, TMS internal standard); δ: 1.85–2.15 (3H, m), 2.15–2.35 (2H, m), 2.75–2.90 (1H, m), 2.90–2.95 (1H, m), 3.20–3.50 (6H, m), 3.70–3.80 (1H, m), 3.85–4.10 (1H, m), 5.14 (1H, brs), 6.14, 6.43 (1H, brs ×2), 7.05–7.40 (9H, m).

40
45
50
55
60
65
70
75
80
85
90
95
100
105
110
115
120
125
130
135
140
145
150
155
160
165
170
175
180
185
190
195
200
205
210
215
220
225
230
235
240
245
250
255
260
265
270
275
280
285
290
295
300
305
310
315
320
325
330
335
340
345
350
355
360
365
370
375
380
385
390
395
400
405
410
415
420
425
430
435
440
445
450
455
460
465
470
475
480
485
490
495
500
505
510
515
520
525
530
535
540
545
550
555
560
565
570
575
580
585
590
595
600
605
610
615
620
625
630
635
640
645
650
655
660
665
670
675
680
685
690
695
700
705
710
715
720
725
730
735
740
745
750
755
760
765
770
775
780
785
790
795
800
805
810
815
820
825
830
835
840
845
850
855
860
865
870
875
880
885
890
895
900
905
910
915
920
925
930
935
940
945
950
955
960
965
970
975
980
985
990
995
1000
1005
1010
1015
1020
1025
1030
1035
1040
1045
1050
1055
1060
1065
1070
1075
1080
1085
1090
1095
1100
1105
1110
1115
1120
1125
1130
1135
1140
1145
1150
1155
1160
1165
1170
1175
1180
1185
1190
1195
1200
1205
1210
1215
1220
1225
1230
1235
1240
1245
1250
1255
1260
1265
1270
1275
1280
1285
1290
1295
1300
1305
1310
1315
1320
1325
1330
1335
1340
1345
1350
1355
1360
1365
1370
1375
1380
1385
1390
1395
1400
1405
1410
1415
1420
1425
1430
1435
1440
1445
1450
1455
1460
1465
1470
1475
1480
1485
1490
1495
1500
1505
1510
1515
1520
1525
1530
1535
1540
1545
1550
1555
1560
1565
1570
1575
1580
1585
1590
1595
1600
1605
1610
1615
1620
1625
1630
1635
1640
1645
1650
1655
1660
1665
1670
1675
1680
1685
1690
1695
1700
1705
1710
1715
1720
1725
1730
1735
1740
1745
1750
1755
1760
1765
1770
1775
1780
1785
1790
1795
1800
1805
1810
1815
1820
1825
1830
1835
1840
1845
1850
1855
1860
1865
1870
1875
1880
1885
1890
1895
1900
1905
1910
1915
1920
1925
1930
1935
1940
1945
1950
1955
1960
1965
1970
1975
1980
1985
1990
1995
2000
2005
2010
2015
2020
2025
2030
2035
2040
2045
2050
2055
2060
2065
2070
2075
2080
2085
2090
2095
2100
2105
2110
2115
2120
2125
2130
2135
2140
2145
2150
2155
2160
2165
2170
2175
2180
2185
2190
2195
2200
2205
2210
2215
2220
2225
2230
2235
2240
2245
2250
2255
2260
2265
2270
2275
2280
2285
2290
2295
2300
2305
2310
2315
2320
2325
2330
2335
2340
2345
2350
2355
2360
2365
2370
2375
2380
2385
2390
2395
2400
2405
2410
2415
2420
2425
2430
2435
2440
2445
2450
2455
2460
2465
2470
2475
2480
2485
2490
2495
2500
2505
2510
2515
2520
2525
2530
2535
2540
2545
2550
2555
2560
2565
2570
2575
2580
2585
2590
2595
2600
2605
2610
2615
2620
2625
2630
2635
2640
2645
2650
2655
2660
2665
2670
2675
2680
2685
2690
2695
2700
2705
2710
2715
2720
2725
2730
2735
2740
2745
2750
2755
2760
2765
2770
2775
2780
2785
2790
2795
2800
2805
2810
2815
2820
2825
2830
2835
2840
2845
2850
2855
2860
2865
2870
2875
2880
2885
2890
2895
2900
2905
2910
2915
2920
2925
2930
2935
2940
2945
2950
2955
2960
2965
2970
2975
2980
2985
2990
2995
3000
3005
3010
3015
3020
3025
3030
3035
3040
3045
3050
3055
3060
3065
3070
3075
3080
3085
3090
3095
3100
3105
3110
3115
3120
3125
3130
3135
3140
3145
3150
3155
3160
3165
3170
3175
3180
3185
3190
3195
3200
3205
3210
3215
3220
3225
3230
3235
3240
3245
3250
3255
3260
3265
3270
3275
3280
3285
3290
3295
3300
3305
3310
3315
3320
3325
3330
3335
3340
3345
3350
3355
3360
3365
3370
3375
3380
3385
3390
3395
3400
3405
3410
3415
3420
3425
3430
3435
3440
3445
3450
3455
3460
3465
3470
3475
3480
3485
3490
3495
3500
3505
3510
3515
3520
3525
3530
3535
3540
3545
3550
3555
3560
3565
3570
3575
3580
3585
3590
3595
3600
3605
3610
3615
3620
3625
3630
3635
3640
3645
3650
3655
3660
3665
3670
3675
3680
3685
3690
3695
3700
3705
3710
3715
3720
3725
3730
3735
3740
3745
3750
3755
3760
3765
3770
3775
3780
3785
3790
3795
3800
3805
3810
3815
3820
3825
3830
3835
3840
3845
3850
3855
3860
3865
3870
3875
3880
3885
3890
3895
3900
3905
3910
3915
3920
3925
3930
3935
3940
3945
3950
3955
3960
3965
3970
3975
3980
3985
3990
3995
4000
4005
4010
4015
4020
4025
4030
4035
4040
4045
4050
4055
4060
4065
4070
4075
4080
4085
4090
4095
4100
4105
4110
4115
4120
4125
4130
4135
4140
4145
4150
4155
4160
4165
4170
4175
4180
4185
4190
4195
4200
4205
4210
4215
4220
4225
4230
4235
4240
4245
4250
4255
4260
4265
4270
4275
4280
4285
4290
4295
4300
4305
4310
4315
4320
4325
4330
4335
4340
4345
4350
4355
4360
4365
4370
4375
4380
4385
4390
4395
4400
4405
4410
4415
4420
4425
4430
4435
4440
4445
4450
4455
4460
4465
4470
4475
4480
4485
4490
4495
4500
4505
4510
4515
4520
4525
4530
4535
4540
4545
4550
4555
4560
4565
4570
4575
4580
4585
4590
4595
4600
4605
4610
4615
4620
4625
4630
4635
4640
4645
4650
4655
4660
4665
4670
4675
4680
4685
4690
4695
4700
4705
4710
4715
4720
4725
4730
4735
4740
4745
4750
4755
4760
4765
4770
4775
4780
4785
4790
4795
4800
4805
4810
4815
4820
4825
4830
4835
4840
4845
4850
4855
4860
4865
4870
4875
4880
4885
4890
4895
4900
4905
4910
4915
4920
4925
4930
4935
4940
4945
4950
4955
4960
4965
4970
4975
4980
4985
4990
4995
5000
5005
5010
5015
5020
5025
5030
5035
5040
5045
5050
5055
5060
5065
5070
5075
5080
5085
5090
5095
5100
5105
5110
5115
5120
5125
5130
5135
5140
5145
5150
5155
5160
5165
5170
5175
5180
5185
5190
5195
5200
5205
5210
5215
5220
5225
5230
5235
5240
5245
5250
5255
5260
5265
5270
5275
5280
5285
5290
5295
5300
5305
5310
5315
5320
5325
5330
5335
5340
5345
5350
5355
5360
5365
5370
5375
5380
5385
5390
5395
5400
5405
5410
5415
5420
5425
5430
5435
5440
5445
5450
5455
5460
5465
5470
5475
5480
5485
5490
5495
5500
5505
5510
5515
5520
5525
5530
5535
5540
5545
5550
5555
5560
5565
5570
5575
5580
5585
5590
5595
5600
5605
5610
5615
5620
5625
5630
5635
5640
5645
5650
5655
5660
5665
5670
5675
5680
5685
5690
5695
5700
5705
5710
5715
5720
5725
5730
5735
5740
5745
5750
5755
5760
5765
5770
5775
5780
5785
5790
5795
5800
5805
5810
5815
5820
5825
5830
5835
5840
5845
5850
5855
5860
5865
5870
5875
5880
5885
5890
5895
5900
5905
5910
5915
5920
5925
5930
5935
5940
5945
5950
5955
5960
5965
5970
5975
5980
5985
5990
5995
6000
6005
6010
6015
6020
6025
6030
6035
6040
6045
6050
6055
6060
6065
6070
6075
6080
6085
6090
6095
6100
6105
6110
6115
6120
6125
6130
6135
6140
6145
6150
6155
6160
6165
6170
6175
6180
6185
6190
6195
6200
6205
6210
6215
6220
6225
6230
6235
6240
6245
6250
6255
6260
6265
6270
6275
6280
6285
6290
6295
6300
6305
6310
6315
6320
6325
6330
6335
6340
6345
6350
6355
6360
6365
6370
6375
6380
6385
6390
6395
6400
6405
6410
6415
6420
6425
6430
6435
6440
6445
6450
6455
6460
6465
6470
6475
6480
6485
6490
6495
6500
6505
6510
6515
6520
6525
6530
6535
6540
6545
6550
6555
6560
6565
6570
6575
6580
6585
6590
6595
6600
6605
6610
6615
6620
6625
6630
6635
6640
6645
6650
6655
6660
6665
6670
6675
6680
6685
6690
6695
6700
6705
6710
6715
6720
6725
6730
6735
6740
6745
6750
6755
6760
6765
6770
6775
6780
6785
6790
6795
6800
6805
681

6,017,927

25

Properties: yellow oil

Elemental analysis (for $C_{21}H_{24}N_2O_3 \cdot 0.3H_2O$);

26

Mass analysis (m/z , EI): 352 (M^+)

The chemical structural formulas of the compounds obtained in Examples 1-19 are shown below in Tables 3-5.

TABLE 3

| Example No. | Structural Formula | Example No. | Structural Formula |
|-------------|--------------------|-------------|--------------------|
| 1 | | 6 | |
| 2 | | 7 | |
| 3 | | 8 | |
| 4 | | 9 | |
| 5 | | 10 | |

| C (%) | H (%) | N (%) | |
|---------------|-------|-------|----|
| Calcd.: 70.49 | 6.93 | 7.83 | 65 |
| Found: 70.35 | 6.83 | 7.63 | |

TABLE 4









| Example No. | Structural Formula | Example No. | Structural Formula |
|----------------|---|----------------|---|
| 11 |  | 15 |  |
| 12 |  | 16 |  |
| 13 |  | 17 |  |
| 14 |  | 18 |  |

TABLE 5


| Example No. | Structural Formula | 5 |
|-------------|--------------------|----|
| 19 | | 10 |
| | | 15 |

TABLE 6-continued

| Example No. | Ring A | Example No. | Ring A |
|-------------|--------|-------------|--------|
| 6-(a) | | 6-(b) | |
| 12-(a) | | 12-(b) | |
| 13-(a) | | 13-(b) | |
| 14-(a) | | 14-(b) | |
| 16-(a) | | 16-(b) | |
| 12 | | 25 | |
| 30 | | 35 | |
| 40 | | 45 | |
| 50 | | 55 | |


Each of the above-described compounds in Examples 3-6, 12-14, 16 and 19 can be obtained as an optical resolved form as shown in the following Tables 6-8 using an optically resolved intermediate in a similar manner to Examples 8-11.

TABLE 7



| Example No. | Ring A |
|-------------|--------|-------------|--------|-------------|--------|-------------|--------|
| 3-(c) | | 3-(d) | | 15 | | 16-(c) | |
| 4-(c) | | 4-(d) | | 20 | | 16-(d) | |
| 5-(c) | | 5-(d) | | 25 | | | |
| 6-(c) | | 6-(d) | | 30 | | 19-(a) | |
| 12-(c) | | 12-(d) | | 35 | | 19-(b) | |
| 13-(c) | | 13-(d) | | 40 | | 19-(c) | |
| 14-(c) | | 14-(d) | | 45 | | 19-(d) | |

TABLE 7-continued




The other compounds embraced by the present invention will be shown in Tables 9-33. They can be synthesized by

TABLE 8

| Example No. | Structural Formula |
|-------------|--------------------|
| 19-(a) | |
| 19-(b) | |
| 19-(c) | |
| 19-(d) | |

any one of the above-described preparation processes, processes described in Examples or processes known to those skilled in the art and do not require any particular experiment. Incidentally, these compounds are described as a racemic compound, but optical active substances based on an asymmetric carbon is also included.


TABLE 9



Compound No. R¹ R² R³ R⁴ X Ring A

| | | | | | | |
|-----|----|---|----|---|---|----|
| A-1 | Cl | H | H | H | — | 25 |
| A-2 | H | H | Cl | H | — | 30 |
| A-3 | Cl | H | Cl | H | — | 35 |
| A-4 | F | H | H | H | — | 40 |
| A-5 | H | H | F | H | — | 45 |
| A-6 | Br | H | H | H | — | 50 |


TABLE 9-continued




15

Compound No. R¹ R² R³ R⁴ X Ring A

20 A-7 H H Br H —



A-8 Cl H Br H —




A-9 CH₃ H H H —



40


TABLE 10



50

Compound No. R¹ R² R³ R⁴ X Ring A

60 A-10 C₂H₅ H H H —



65

TABLE 10-continued

| Compound No. | Chemical Structure of Compound 35 | | | | | |
|--------------|-----------------------------------|-------------------------------|-------------------------------|----------------|---|--------|
| | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
| A-11 | n-C ₃ H ₇ | H | H | H | — | |
| A-12 | i-C ₃ H ₇ | H | H | H | — | |
| A-13 | H | CH ₃ | H | H | — | |
| A-14 | H | C ₂ H ₅ | H | H | — | |
| A-15 | H | H | CH ₃ | H | — | |
| A-16 | H | R | C ₂ H ₅ | H | — | |


TABLE 10-continued

| Compound No. | Chemical Structure of Compound 36 | | | | | |
|--------------|-----------------------------------|-----------------|-----------------|-----------------|---|--------|
| | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
| A-17 | CH ₃ | H | CH ₃ | H | — | |
| A-18 | H | CH ₃ | CH ₃ | H | — | |
| A-19 | CH ₃ | H | CH ₃ | CH ₃ | — | |
| A-20 | Cl | H | H | H | — | |

TABLE 11

| Compound No. | Chemical Structure of Compound 37 | | | | | |
|--------------|-----------------------------------|----------------|-----------------|-----------------|---|--------|
| | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
| A-19 | CH ₃ | H | CH ₃ | CH ₃ | — | |
| A-20 | Cl | H | H | H | — | |

TABLE 11-continued









| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|-----------------|----------------|----------------|----------------|----------------|---|---|
| A-21 | H | H | Cl | H | — |  |
| A-22 | H | H | Cl | H | — |  |
| A-23 | H | H | Cl | H | — |  |
| A-24 | H | H | Cl | H | — |  |
| A-25 | H | H | Cl | H | — |  |

TABLE 12




| 15 | Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|----|--------------|----------------|-----------------|-----------------|----------------|---|---|
| 20 | A-26 | H | H | CH ₃ | H | — |  |
| 25 | A-27 | Cl | H | H | H | — |  |
| 30 | A-28 | H | CH ₃ | H | H | — |  |
| 35 | A-29 | Cl | H | H | H | — |  |
| 40 | A-30 | Cl | H | H | H | — |  |
| 45 | A-31 | H | H | Cl | H | — |  |
| 50 | A-32 | H | H | Cl | H | — |  |

6,017,927


39



TABLE 12-continued



| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|-----------------|----------------|----------------------|------------------|----------------|---|---|
| A-33 | H | OCH ₃ | OCH ₃ | H | — |  |
| A-34 | H | —OCH ₂ O— | H | — |  | |


TABLE 13






| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|-----------------|----------------|----------------|----------------|----------------|-----------------|---|
| A-35 | H | H | H | H | CH ₂ |  |
| A-36 | H | H | H | H | CH ₂ |  |

40

TABLE 13-continued



| 15 | Compound | No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|----|----------|-----|----------------|----------------|----------------|----------------|-----------------|---|
| 20 | A-37 | | H | H | H | H | CH ₂ |  |
| 25 | | | | | | | |  |
| 30 | A-38 | | H | H | H | H | CH ₂ |  |



60

41




TABLE 14

| Compound No. | Ring A |
|--------------|--------|
| B-1 | |
| B-2 | |
| B-3 | |
| B-4 | |
| B-5 | |
| B-6 | |
| B-7 | |

42




TABLE 14-continued

| | | |
|----|-----------------|--------|
| 5 | | |
| 10 | Compound No. | Ring A |
| 15 | | |
| 20 | B-8 | |
| 25 | B-9 | |
| 30 | B-10 | |
| 35 | B-11 | |
| 40 | | |
| 45 | B-12 | |
| 50 | | |
| 55 | | |
| 60 | | |

TABLE 15






TABLE 15-continued




| Compound No. | Ring A | | Compound No. | Ring A |
|--------------|--------|----|--------------|--------|
| B-13 | | 15 | B-19 | |
| B-14 | | 20 | B-20 | |
| B-15 | | 25 | B-21 | |
| B-16 | | 30 | B-22 | |
| B-17 | | 35 | B-23 | |
| B-18 | | 40 | B-24 | |
| | | 45 | | |
| | | 50 | | |
| | | 55 | | |
| | | 60 | | |
| | | 65 | | |

TABLE 16




| Compound No. | Ring A |
|-----------------|--------|
| B-25 | |
| B-26 | |
| B-27 | |
| B-28 | |
| B-29 | |
| B-30 | |

TABLE 16-continued



| Compound No. | Ring A |
|--------------|--------|
| 15 | |
| 20 | B-31 |
| 25 | B-32 |
| 30 | B-33 |
| 35 | B-34 |
| 40 | B-35 |
| 45 | B-36 |
| 50 | |
| 55 | |
| 60 | |
| 65 | |

TABLE 17



Compound No.


Ring A

5

10


15

B-37



20


B-38



25

30


B-39



35


40

B-40




45

B-41



55


B-42



60

65

TABLE 17-continued




Compound No.

Ring A


15

B-43




20

B-44




30

B-45




35

B-46




40

B-47



55


B-48



60


65

TABLE 18


Compound
No.

Ring A


B-49




B-50




B-51




B-52




B-53




B-54



B-55




B-56




5

10

Compound
No.


Ring A

B-57




15

B-58




20

B-59



25


B-60



30

35

TABLE 19




45

50

Compound
No.


Ring A

B-61



55


B-62



60

65


TABLE 19-continued




Compound No.

Ring A


B-63




B-64




B-65




B-66




B-67




B-68



B-69



B-70



5

10

15

20

25

30

35

40

45


50

55

60

65


TABLE 19-continued



Compound No.

Ring A

B-71



B-72






TABLE 20




Compound No.

Ring A

B-73



B-74



B-75





TABLE 21



X⁺

| Compound No. | Ring A | 15 | Compound No. | Ring A |
|--------------|--------|----|--------------|--------|
| B-76 | | | B-82 | |
| B-77 | | 20 | B-83 | |
| B-78 | | 25 | B-84 | |
| B-79 | | 30 | B-85 | |
| B-80 | | 35 | B-86 | |
| B-81 | | 40 | B-87 | |
| | | 45 | | |
| | | 50 | | |
| | | 55 | | |
| | | 60 | | |
| | | 65 | | |

TABLE 22






TABLE 22-continued



| Compound No. | Ring A | | Compound No. | Ring A |
|--------------|--------|----|--------------|--------|
| B-88 | | 15 | B-94 | |
| B-89 | | 20 | B-95 | |
| B-90 | | 25 | B-96 | |
| B-91 | | 30 | B-97 | |
| B-92 | | 35 | B-98 | |
| B-93 | | 40 | B-99 | |
| | | 45 | | |
| | | 50 | | |
| | | 55 | | |
| | | 60 | | |
| | | 65 | | |

TABLE 23










| Compound No. | Ring A |
|--------------|---|
| B-100 |  |
| B-101 |  |
| B-102 |  |
| B-103 |  |
| B-104 |  |
| B-105 |  |
| B-106 |  |

TABLE 23-continued









| Compound No. | Ring A |
|-----------------|--|
| 15 | B-107 |
| 20 |  |
| 25 | B-108 |
| 30 |  |
| 35 | B-109 |
| 40 |  |
| 45 | B-110 |
| 50 |  |
| 55 | B-111 |
| 60 |  |


TABLE 24



59Compound
No.


Ring A

B-112




5

B-113




10

B-114




20

B-115




30

B-116




35

B-117




40

B-118



45


B-119




50

60


B-120



B-121



B-122



B-123






TABLE 25

Compound
No.

Ring A

B-124



B-125




TABLE 25-continued

| Compound No. | Ring A | |
|--------------|--------|----|
| B-126 | | 15 |
| B-127 | | 20 |
| B-128 | | 25 |
| B-129 | | 30 |
| B-130 | | 35 |
| B-131 | | 40 |
| B-132 | | 45 |
| B-133 | | 50 |

TABLE 25-continued

| Compound No. | Ring A | |
|--------------|--------|----|
| B-134 | | 15 |
| B-135 | | 20 |
| | | 25 |
| | | 30 |
| | | 35 |
| | | 40 |
| | | 45 |
| B-136 | | 50 |
| B-137 | | 55 |
| B-138 | | 60 |
| B-139 | | 65 |

TABLE 26

TABLE 26-continued

| Compound No. | Ring A | | Compound No. | Ring A |
|--------------|--------|----|--------------|--------|
| B-140 | | 15 | B-148 | |
| B-141 | | 20 | B-149 | |
| B-142 | | 25 | B-150 | |
| B-143 | | 30 | B-151 | |
| B-144 | | 35 | B-152 | |
| B-145 | | 40 | B-153 | |
| B-146 | | 45 | B-154 | |
| B-147 | | 50 | B-155 | |
| | | 55 | | |
| | | 60 | | |
| | | 65 | | |

TABLE 27




TABLE 27-continued


| | |
|---|----|
|  X^- $(X = \text{Br}, \text{I})$ | 5 |
| | 10 |
| | 15 |
| | 20 |
| | 25 |

TABLE 29












| | |
|--|----|
|  Compound No. Ring A | 5 |
| | 10 |
| B-159 | 15 |
|  | 20 |
| B-160 | 25 |
|  | 30 |
| B-161 | 35 |
|  | 40 |
| B-162 | 45 |
|  | 50 |
| B-163 | 55 |
|  | 60 |
| B-164 | 65 |
|  | |
| B-165 | |
|  | |

TABLE 28

| | |
|---|----|
|  Compound No. Ring A | 30 |
| | 35 |
| B-157 | 40 |
|  | 45 |
| B-158 | 50 |
|  | 55 |
| | 60 |

67


TABLE 29-continued



| Compound No. | Ring A |
|-----------------|--|
| B-166 |  |
| B-167 |  |
| B-168 |  |

TABLE 30


— 40



| Compound No. | Ring A | |
|--------------|---|----|
| B-169 |  | 55 |
| B-170 |  | 60 |

68

TABLE 30-continued





| Compound No. | Ring A |
|--------------|---|
| B-171 |  |
| B-172 |  |
| B-173 |  |
| B-174 |  |
| B-175 |  |
| B-176 |  |
| B-177 |  |
| B-178 |  |

TABLE 30-continued



| Compound No. | Ring A |
|-----------------|--------|
|-----------------|--------|

TABLE 31

20
Compound
No. Ring A

B-179

25

30

The chemical structure shows a benzene ring with a chlorine atom (Cl) attached to one of the carbon atoms.

B-180

B-181

B-182

B-183

B-184

TABLE 31-continued

| 5 | Compound No. | Ring A |
|----|-----------------|---|
| | B-185 | |
| 10 | |  |

B-186

15 

20 B-187

25



The chemical structure of 2-methylfuran is shown. It consists of a five-membered furan ring with a methyl group (a single vertical line) attached to the second carbon atom from the oxygen.

TABLE 32

TABLE 32

Compound

| No. | R _a |
|-----|----------------|
| 45 | R-188 |

K-189


B-169

B-190

B-190

60  61

TABLE 33








| Compound No. | Ring A |
|--------------|---|
| B-191 |  |
| B-192 |  |
| B-193 |  |
| B-194 |  |
| B-195 |  |
| B-196 |  |
| B-197 |  |


TABLE 33-continued



| | Compound No. | Ring A |
|----|-----------------|--|
| 15 | B-198 |  |
| 20 | B-199 |  |

We claim:

30 1. A quinuclidine derivative represented by the following formula (I):



where the symbols in the formula have the following meanings:

Ring A:

(1) an aryl group having 6 to 14 carbon atoms
 (2) a cycloalkyl group having 3 to 8 carbon atoms
 (3) a cycloalrenye group having 3 to 8 carbon atoms;
 wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group, and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or mono- or di-lower alkylamino group

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2,

a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof.

2. The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 1, wherein R represents a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group, and the ring A represents an aryl group having 6 to 14 carbon atoms, a cycloalkyl group having 3 to 8 carbon atoms or a cycloalkenyl group having 3 to 8 carbon atoms, in which said ring may be substituted by a halogen atom, a lower alkyl group, a hydroxyl group, a lower alkoxy group, a nitro group, a cyano group, an amino group or a mono- or di-lower alkylamino group.


3. The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 2, wherein m is 0, and the ring A represents an aryl group, a cycloalkyl group or a cycloalkenyl group which may be substituted by a halogen atom, a lower alkyl group, a hydroxyl group or a lower alkoxy group.

4. The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to claim 3, wherein the ring A represents a phenyl group which may be substituted by a halogen atom or a lower alkyl group, or cycloalkyl group.

5. The quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to any one of claims 2 to 4, wherein X represents a single bond.

6. A quinuclidine derivative, a salt thereof, or a quaternary ammonium salt thereof according to any one of claim 1, which is selected from the group consisting of 3-quinuclidinyl 1-phenyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1-(4-chlorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1-(4-fluorophenyl)-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate, 3-quinuclidinyl 1,2,3,4-tetrahydro-1-(4-tolyl)-2-isoquinolinecarboxylate, and 3-quinuclidinyl 1-cyclohexyl-1,2,3,4-tetrahydro-2-isoquinolinecarboxylate.

7. A pharmaceutical composition which comprises a quinuclidine derivative represented by the following formula (I):



where the symbols in the formula have the following meanings:

Ring A:

(1) an aryl group having 6 to 14 carbon atoms
 (2) a cycloalkyl group having 3 to 8 carbon atoms
 (3) a cycloalkenyl group having 3 to 8 carbon atoms;
 wherein groups (1) to (5) above may be unsubstituted or substituted by one or more substituents selected from the group consisting of a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group and a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group

X: a single bond or a methylene group;

R: a halogen atom, a hydroxyl group, a lower alkoxy group, a carboxyl group, a lower alkoxy carbonyl group, a lower acyl group, a mercapto group, a lower alkylthio group, a sulfonyl group, a lower alkylsulfonyl group, a sulfinyl group, a lower alkylsulfinyl group, a sulfonamido group, a lower alkanesulfonamido group, a carbamoyl group, a thiocarbamoyl group, a mono- or di-lower alkylcarbamoyl group, a nitro group, a cyano group, an amino group, a mono- or di-lower alkylamino group, a methylenedioxy group, an ethylenedioxy group or a lower alkyl group which may be substituted by a halogen atom, a hydroxyl group, a lower alkoxy group, an amino group or a mono- or di-lower alkylamino group;

l: 0 or 1;

m: 0 or an integer of 1 to 3, and

n: an integer of 1 or 2, or a salt thereof, an N-oxide thereof, or a quaternary ammonium salt thereof,

and a pharmaceutically acceptable carrier.

* * * * *

ATTACHMENT 3A

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 1 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 14,

Lines 22 and 25, delete "(1R)" and insert -- (1S) --;
Lines 35 and 53, delete "C" and insert -- c -- (i.e. small letter); and
Lines 41 and 43, delete "(1S)" and insert -- (1R) --.

Column 21,

Lines 14 and 44, delete "(1R)" and insert -- (1S) --;
Line 31, delete "(1R,3'RS)" and insert -- (1S,3'RS) --; and
Line 63, delete "(1R,3'R)" and insert -- (1S,3'R) --.

Column 22,

Line 16, delete "(1S,3'S)" and insert -- (1R,3'S) --;
Lines 19 and 37, delete "(1S)" and insert -- (1R) --;
Line 34, delete "(1S,3'R)" and insert -- (1R,3'R) --;
Line 53, delete "(1R,3'S)" and insert -- (1S,3'S) --; and
Line 56, delete "(1R)" and insert -- (1S) --.

Column 24,

Line 19, delete "(1R,3'R)" and insert -- (1S, 3'R) --;
Lines 31 and 50, delete "(1'R,3R)" and insert -- (1'S,3R) --; and
Line 44, delete "(1R,3'R)" and insert -- (1S,3'R) --.


Columns 33 to 40,

Tables 9 to 13, "R₂" and "R₃" should be changed to -- R² -- and -- R³ --.

Column 16,

Table 1, Example No. 7, the chemical formula should be changed as follows:

Table 1
Example 7



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.


Page 2 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 17,

Table 1, Example No. 8, the chemical formula should be changed as follows:


Table 1
Example 8



Column 26,

Table 3, Example No. 7, the chemical formula should be changed as follows:

Table 3
Example 7



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 3 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26 (cont'd),

Table 3, Example No. 8, the chemical formula should be changed as follows:

Table 3
Example 8





Table 3, Example No. 9, the chemical formula should be changed as follows:

Table 3
Example 9



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.



Page 4 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26 (cont'd)

Table 3, Example No. 10, the chemical formula should be changed as follows:



Table 3
Example 10



Column 27.

Table 4, Example No. 11, the chemical formula should be changed as follows:

Table 4
Example 11



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 5 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 28,

Table 4, Example No.17, the chemical formula should be changed as follows:

Table 4
Example 17





Table 4, Example No. 18, the chemical formula should be changed as follows:

Table 4
Example 18



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 6 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39.

Delete Tables 9 to 12, and replace with the following:

TABLE 9

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|----------------|----------------|----------------|----------------|---|---|
| A-1 | Cl | H | H | H | — |  |
| A-2 | H | H | Cl | H | — |  |
| A-3 | Cl | H | Cl | H | — |  |
| A-4 | F | H | H | H | — |  |
| A-5 | H | H | F | H | — |  |
| A-6 | Br | H | H | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 7 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).
Delete Tables 9 to 12, and replace with the following:

TABLE 9-continued

| Compound No. |  | | | | |
|--------------|---|----------------|----------------|----------------|---|
| | R ¹ | R ² | R ³ | R ⁴ | X |
| A-7 | H | H | Br | H | — |
| | | | | |  |
| A-8 | Cl | H | Br | H | — |
| | | | | |  |
| A-9 | CH ₃ | H | H | H | — |
| | | | | |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.






Page 8 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 10

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|---------------------------------|-------------------------------|----------------|----------------|---|---|
| A-10 | C ₂ H ₅ | H | H | H | — |  |
| A-11 | —C ₂ H ₅ | H | H | H | — |  |
| A-12 | i-C ₃ H ₇ | H | H | H | — |  |
| A-13 | H | CH ₃ | H | H | — |  |
| A-14 | H | C ₂ H ₅ | H | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 9 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).
Delete Tables 9 to 12, and replace with the following:

TABLE 10-continued



Compound
No. R¹ R² R³ R⁴ X Ring A

| | | | | | | |
|------|-----------------|-----------------|-------------------------------|---|---|---|
| A-15 | H | H | CH ₃ | H | — |  |
| A-16 | H | R | C ₂ H ₅ | H | — |  |
| A-17 | CH ₃ | H | CH ₃ | H | — |  |
| A-18 | H | CH ₃ | CH ₃ | H | — |  |


UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 10 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).
Delete Tables 9 to 12, and replace with the following:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.



Page 11 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 11-continued

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|-----------------|----------------|----------------|----------------|----------------|---|---|
| A-24 | H | H | Cl | H | - |  |
| A-25 | H | H | Cl | H | - |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 12 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION




PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 13 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).
Delete Tables 9 to 12, and replace with the following:

TABLE 12-continued

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|----------------|----------------------|------------------|----------------|---|---|
| A-31 | H | H | Cl | H | - |  |
| A-32 | H | H | Cl | H | - |  |
| A-33 | H | OCH ₃ | OCH ₃ | H | - |  |
| A-34 | H | -OCH ₂ O- | H | - | |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.


Page 14 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 53.

Table 21, Column B-77, the chemical formula should be changed as follows:

Table 21
Compound B-77



Column 62.

Table 25, Compound B-134, the chemical formula should be changed as follows:

Table 25
Compound B-134



Column 63.

Table 26, Compound B-145, the chemical formula should be changed as follows:

Table 26
Compound B-145



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 15 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


Column 65,
Table 28, the chemical formula should be changed as follows:

Table 28



Column 69,
Table 31, the following chemical formula is missing:

Table 31



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Masamitsu Tsukamoto et al.

Page 16 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 72.

Line 22, "cycloakeny" should be corrected to -- cycloalkenyl --;
Line 45, "akylsulfonyl" should be corrected to -- alkylsulfonyl --;
Line 49, "cycloalrenye" should be corrected to -- cycloalkenyl --.

Column 74.

Line 22, "cycloakeny" should be corrected to -- cycloalkenyl --;
Line 45, "akylsulfonyl" should be corrected to -- alkylsulfonyl --.

Signed and Sealed this

Twenty-fifth Day of February, 2003



JAMES E. ROGAN
Director of the United States Patent and Trademark Office

ATTACHMENT 3B

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 1 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 14.

Lines 22 and 25, delete "(1R)" and insert -- (1S) --;
Lines 35 and 53, delete "C" and insert -- c -- (i.e. small letter); and
Lines 41 and 43, delete "(1S)" and insert -- (1R) --.

Column 21.

Lines 14 and 44, delete "(1R)" and insert -- (1S) --;
Line 31, delete "(1R,3'RS)" and insert -- (1S,3'RS) --; and
Line 63, delete "(1R,3'R)" and insert -- (1S,3'R) --.

Column 22.

Line 16, delete "(1S,3'S)" and insert -- (1R,3'S) --;
Lines 19 and 37, delete "(1S)" and insert -- (1R) --;
Line 34, delete "(1S,3'R)" and insert -- (1R,3'R) --;
Line 53, delete "(1R,3'S)" and insert -- (1S,3'S) --; and
Line 56, delete "(1R)" and insert -- (1S) --.

Column 24.

Line 19, delete "(1R,3'R)" and insert -- (1S, 3'R) --;
Lines 31 and 50, delete "(1'R,3R)" and insert -- (1'S,3R) --; and
Line 44, delete "(1R,3'R)" and insert -- (1S,3'R) --.


Columns 33 to 40.

Tables 9 to 13, "R₂" and "R₃" should be changed to -- R² -- and -- R³ --.

Column 16.

Table 1, Example No. 7, the chemical formula should be changed as follows:

Table 1
Example 7



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 2 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:


Column 17,
Table 1, Example No. 8, the chemical formula should be changed as follows:

Table 1
Example 8



Column 26,
Table 3, Example No. 7, the chemical formula should be changed as follows:

Table 3
Example 7



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 3 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26 (cont'd),

Table 3, Example No. 8, the chemical formula should be changed as follows:

Table 3
Example 8





Table 3, Example No. 9, the chemical formula should be changed as follows:

Table 3
Example 9



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.


Page 4 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 26 (cont'd)

Table 3, Example No. 10, the chemical formula should be changed as follows:


Table 3
Example 10



Column 27

Table 4, Example No. 11, the chemical formula should be changed as follows:

Table 4
Example 11



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 5 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 28,

Table 4, Example No.17, the chemical formula should be changed as follows:

Table 4
Example 17





Table 4, Example No. 18, the chemical formula should be changed as follows:

Table 4
Example 18



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 6 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39,

Delete Tables 9 to 12, and replace with the following:

TABLE 9

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|----------------|----------------|----------------|----------------|---|---|
| A-1 | Cl | H | H | H | — |  |
| A-2 | H | H | Cl | H | — |  |
| A-3 | Cl | H | Cl | H | — |  |
| A-4 | F | H | H | H | — |  |
| A-5 | H | H | F | H | — |  |
| A-6 | Br | H | H | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.


Page 7 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 9-continued

| Compound No. |  | | | | |
|--------------|---|----------------|----------------|----------------|---|
| | R ¹ | R ² | R ³ | R ⁴ | X |
| A-7 | H | H | Br | H | — |
| | | | | |  |
| A-8 | Cl | H | Br | H | — |
| | | | | |  |
| A-9 | CH ₃ | H | H | H | — |
| | | | | |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.






Page 8 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd),

Delete Tables 9 to 12, and replace with the following:

TABLE 10

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|-----------------|--------------------------------|-------------------------------|----------------|----------------|---|---|
| A-10 | C ₆ H ₅ | H | H | H | — |  |
| A-11 | nC ₆ H ₅ | H | H | H | — |  |
| A-12 | iC ₆ H ₅ | H | H | H | — |  |
| A-13 | H | CH ₃ | H | H | — |  |
| A-14 | H | C ₆ H ₅ | H | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.


Page 9 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 10-continued



| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|----------------|----------------|----------------|----------------|---|--------|
|--------------|----------------|----------------|----------------|----------------|---|--------|

| | | | | | | |
|------|-----------------|-----------------|-------------------------------|---|---|---|
| A-15 | H | H | CH ₃ | H | — |  |
| A-16 | H | R | C ₂ H ₅ | H | — |  |
| A-17 | Cl ₃ | H | CH ₃ | R | — |  |
| A-18 | H | Cl ₃ | CH ₃ | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION


PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 10 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.




Page 11 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 11-continued



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.





Page 12 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 12

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A |
|--------------|----------------|-----------------|-----------------|----------------|---|---|
| A-26 | H | H | CH ₃ | H | — |  |
| A-27 | Cl | H | H | H | — |  |
| A-28 | H | CH ₃ | H | H | — |  |
| A-29 | Cl | H | H | H | — |  |
| A-30 | Cl | H | H | H | — |  |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 13 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 33 to 39 (cont'd).

Delete Tables 9 to 12, and replace with the following:

TABLE 12-continued

| Compound No. | R ¹ | R ² | R ³ | R ⁴ | X | Ring A | |
|-----------------|----------------|----------------------|------------------|----------------|---|--------|---|
| | | | | | | — | — |
| A-31 | H | H | Cl | H | — | | |
| A-32 | H | H | Cl | H | — | | |
| A-33 | H | OCH ₃ | OCH ₃ | H | — | | |
| A-34 | H | —OCH ₂ O— | H | — | | | |

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.


Page 14 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 53.

Table 21, Column B-77, the chemical formula should be changed as follows:

Table 21
Compound B-77



Column 62.

Table 25, Compound B-134, the chemical formula should be changed as follows:

Table 25
Compound B-134



Column 63.

Table 26, Compound B-145, the chemical formula should be changed as follows:

Table 26
Compound B-145



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.


Page 15 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 65,

Table 28, the chemical formula should be changed as follows:


Table 28



Column 69,

Table 31, the following chemical formula is missing:

Table 31



UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 6,017,927
DATED : January 25, 2000
INVENTOR(S) : Makoto Takeuchi et al.

Page 16 of 16

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 72.

Line 22, "cycloakenyl" should be corrected to -- cycloalkenyl --;
Line 45, "akylsulfonyl" should be corrected to -- alkylsulfonyl --;
Line 49, "cycloalrenye" should be corrected to -- cycloalkenyl --.

Column 74.

Line 22, "cycloakenyl" should be corrected to -- cycloalkenyl --;
Line 45, "akylsulfonyl" should be corrected to -- alkylsulfonyl --.

This certifies supersedes Certificate of Correction issued February 25, 2003.

Signed and Sealed this

Seventeenth Day of June, 2003



JAMES E. ROGAN
Director of the United States Patent and Trademark Office

ATTACHMENT 3C



Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

Customer No

MFPC

SUGHRUE MION ZINN MACPEAK & SEAS
2100 AVENUE NW
WASHINGTON DC 20037-3202

MAINTENANCE FEE STATEMENT

The data shown below is from the records of the Patent and Trademark Office. If the maintenance fees and any necessary surcharges have been timely paid for the patents listed below, the notation "PAID" will appear in column 11, "STAT" below.

If a maintenance fee payment is defective, the reason is indicated by code in column 11, "STAT" below. TIMELY CORRECTION IS REQUIRED IN ORDER TO AVOID EXPIRATION OF THE PATENT. NOTE 37 CFR 1.377. THE PAYMENT(S) WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION. IF PAYMENT OR CORRECTION IS SUBMITTED DURING THE GRACE PERIOD, A SURCHARGE IS ALSO REQUIRED. NOTE 37 CFR 1.20(h).

If the statement of small entity status is defective the reason is indicated below in column 10 for the related patent number. THE STATEMENT OF SMALL ENTITY STATUS WILL BE ENTERED UPON RECEIPT OF ACCEPTABLE CORRECTION.

| ITEM NUMBER | PATENT NUMBER | FEE CDE | FEE AMT | SUR CHARGE | APPLICATION NUMBER | PATENT DATE | FILE DATE | PAY YR | SML ENT | STAT |
|----------------|------------------|------------|------------|---------------|-----------------------|----------------|--------------|-----------|------------|------|
| 1 | 6,017,927 | 1551 | 890 | 0 | 08/860,377 | 01/25/00 | 08/28/97 | 04 | NO | PAID |

Atty
Item Dkt Number

1 Q45752

DIRECT YOUR RESPONSE TOGETHER WITH ANY QUESTIONS ABOUT THIS NOTICE TO:
Mail Stop: M. Correspondence, Director of the United States Patent & Trademark Office
P.O. Box 1450, Alexandria, VA 22313-1450

ATTACHMENT 4